Method of treating tumor by combination of il-7 protein and immune checkpoint inhibitor

Combining IL-7 protein with PD-1 pathway inhibitors addresses the limitations of current cancer treatments by reducing tumor volume and enhancing immune response in lymphopenic patients, providing a more effective therapeutic approach for metastatic or refractory solid tumors.

JP2024167278AActive Publication Date: 2024-12-03NEOIMMUNETECH INC +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024141869
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-09-05
Filing Date
2024-08-23
Publication Date
2024-12-03
Estimated Expiration
2039-11-15

AI Technical Summary

Technical Problem

Current cancer treatments, including chemotherapy and radiation therapy, often cause lymphopenia, and immune checkpoint inhibitors show limited efficacy in patients with certain malignancies, leading to poor prognosis and resistance, necessitating new therapeutic options with improved safety and efficacy, especially for lymphopenic patients.

Method used

Administering interleukin-7 (IL-7) protein in combination with Programmed Death-1 (PD-1) pathway inhibitors to treat tumors, which can reduce tumor volume and increase tumor-infiltrating lymphocytes (TILs) even in lymphopenic subjects, enhancing the immune response against cancer.

Benefits of technology

The combination therapy significantly reduces tumor volume and increases TILs, offering a promising treatment option for patients with lymphopenia and metastatic or refractory solid tumors, improving treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167278000002
    Figure 2024167278000002
  • Figure 2024167278000003
    Figure 2024167278000003
  • Figure 2024167278000004
    Figure 2024167278000004
Patent Text Reader

Abstract

To provide a method of treating a tumor.SOLUTION: A method of treating a tumor of a human subject who needs treatment of the tumor includes administering an effective amount of interleukin-7(IL-7) protein in combination with an effective amount of Programmed Death-1(PD-1) pathway inhibitor to the subject, where a tumor volume in the subject after the administration is reduced compared to a reference tumor volume after administration of either the PD-1 pathway inhibitor alone or IL-7 protein alone.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This PCT application claims the benefit of priority to U.S. Provisional Application No. 62 / 768,355, filed November 16, 2018, No. 62 / 826,734, filed March 29, 2019, and No. 62 / 896,484, filed September 5, 2019, each of which is incorporated by reference in its entirety herein.

[0002] Reference to sequence listings submitted electronically via EFS-WEB The contents of the Sequence Listing submitted with this application, submitted electronically as an ASCII text file (Name: 4241_002PC03_SequenceListing_ST25.txt, Size: 78,087 bytes, Created: November 14, 2019), are incorporated herein by reference in their entirety. [Background technology]

[0003] Human cancers contain numerous genetic and epigenetic changes that generate neoantigens that may be recognizable by the immune system. Sjoblom et al., Science 314:268-74(2006). The adaptive immune system is composed of T and B lymphocytes and has a strong anticancer potential, a broad ability to respond to various tumor antigens, and fine specificity. Furthermore, the immune system exhibits remarkable plasticity and memory elements. If all these attributes of the adaptive immune system could be harnessed, immunotherapy would be unique among all cancer treatment modalities.

[0004] Cancer immunotherapy has become well established in recent years and is one of the most successful treatment options currently available for many cancer patients. Scott, AM, et al., Cancer Immun 12:14 (2012). Antibodies can not only target antigens involved in cancer cell proliferation and survival, but also activate or antagonize immunological pathways important for cancer immune surveillance. Intensive efforts have also led to the successful development of several immune checkpoint pathway inhibitors, some of which have been approved by the U.S. Food and Drug Administration, such as the anti-CTLA-4 antibody ipilimumab (YERVOY®), the anti-PD-1 antibody nivolumab (OPDIVO®), and pembrolizumab (KEYTRUDA®), and the anti-PD-L1 antibodies atezolizumab (TECENTRIQ®), durvalumab (IMFINZI®), and avelumab (BAVENCIO®). Despite these advances, patients with certain malignancies (e.g., metastatic or refractory solid tumors) still have a very poor prognosis. Only a small proportion of such patients actually experience long-term remission of their cancer, and many patients either do not respond to antibodies or respond initially to antibodies but eventually develop resistance. Sharma, P., et al., Cell 168(4):707-723(2017). Furthermore, many of the available standard-of-care cancer treatments (e.g., chemotherapy and radiation therapy) are known to cause lymphopenia, and many cancer patients are lymphopenic. Grossman, SA, et al., J Natl Compr Canc Netw 13(10):1225-31(2015). Checkpoint inhibitors such as anti-PD-1 antibodies have been shown to have limited efficacy in such cancer patients. Yarchoan, M., et al., J Clin Oncol 35:e14512(2017). Thus, there remains a need for new therapeutic options with acceptable safety profiles and high efficacy in cancer patients, including lymphopenic patients. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Sjoblom et al.,Science 314:268-74(2006) [Non-Patent Document 2] Scott,AM,et al.,Cancer Immun 12:14(2012) [Non-Patent Document 3] Sharma,P.,et al.,Cell 168(4):707-723(2017) [Non-Patent Document 4] Grossman, SA, et al., J Natl Compr Canc Netw 13(10):1225-31(2015) [Non-Patent Document 5] Yarchoan, M., et al., J Clin Oncol 35:e14512(2017) Summary of the Invention

[0006] Provided herein are methods of treating a tumor in a subject in need thereof comprising administering to a human subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of a Programmed Death-1 (PD-1) pathway inhibitor, wherein tumor volume is reduced in the subject following administration as compared to a reference tumor volume following administration of either the PD-1 pathway inhibitor alone or the IL-7 protein alone. In some embodiments, the tumor volume is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% following administration.

[0007] In some embodiments, the methods of the disclosure increase the number of tumor infiltrating lymphocytes (TILs) in a tumor following administration, as compared to the number of TILs in a tumor following administration of either a PD-1 pathway inhibitor alone or an IL-7 protein alone. In certain embodiments, the TILs are CD4 + In another embodiment, the TIL is a CD8 + TIL. In some embodiments, the number of TILs is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after administration.

[0008] In some embodiments, the human subject exhibits lymphopenia prior to administration (ie, as described herein).

[0009] Also provided herein is a method of treating a tumor in a subject in need thereof, comprising administering to the subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of a Programmed Death-1 (PD-1) pathway inhibitor, wherein the subject exhibits lymphopenia.

[0010] In some embodiments, the human subject exhibiting lymphopenia has T lymphopenia, B lymphopenia, and / or NK lymphopenia. In some embodiments, the lymphopenia is caused by or associated with a tumor. In certain embodiments, the lymphopenia is caused by or associated with a previous therapy for a tumor. In further embodiments, the lymphopenia is caused by infection, chronic right ventricular failure, Hodgkin's disease and cancers of the lymphatic system, leukemia, thoracic duct leakage or rupture, side effects of prescription drugs including anti-cancer drugs (e.g., chemotherapy), antiviral drugs, and glucocorticoids, malnutrition caused by a low protein diet, radiation therapy, uremia, autoimmune disorders, immune deficiency syndromes, high stress levels, trauma, thymectomy, or a combination thereof. In certain embodiments, the lymphopenia is idiopathic. In certain embodiments, the lymphopenia includes idiopathic CD4 positive T lymphopenia (ICL), acute radiation syndrome (ARS), or a combination thereof.

[0011] In some embodiments, lymphopenia is characterized by a circulating total lymphocyte count that is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% lower than the total circulating lymphocyte count of a corresponding subject not exhibiting lymphopenia. In certain embodiments, lymphopenia is characterized by a circulating total lymphocyte count that is less than about 1,500 lymphocytes per μL, less than about 1,000 lymphocytes per μL, less than about 800 lymphocytes per μL, less than about 500 lymphocytes per μL, or less than about 200 lymphocytes per μL.

[0012] In some embodiments, the number of tumor infiltrating lymphocytes (TILs) in the tumor of a subject exhibiting lymphopenia is increased after administration, compared to the number of TILs in the tumor after administration of either a PD-1 pathway inhibitor alone or an IL-7 protein alone. In certain embodiments, the number of TILs is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after administration. In some embodiments, the TILs are CD4 + In some embodiments, the TILs are CD8 + T cells.

[0013] In some embodiments, the IL-7 protein is not wild-type IL-7.

[0014] In some embodiments, the IL-7 protein comprises an oligopeptide consisting of 1-10 amino acid residues. In certain embodiments, the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, and glycine-glycine-glycine. In some embodiments, the oligopeptide is methionine-glycine-methionine.

[0015] In some embodiments, the IL-7 protein comprises a half-life extending moiety. In certain embodiments, the half-life extending moiety comprises Fc, albumin, albumin binding polypeptide, Pro / Ala / Ser (PAS), C-terminal peptide of the beta subunit of human chorionic gonadotropin (CTP), polyethylene glycol (PEG), long unstructured hydrophilic amino acid sequence (XTEN), hydroxyethyl starch (HES), albumin binding small molecule, or a combination thereof.

[0016] In some embodiments, the half-life extending moiety is an Fc. In certain embodiments, the Fc is a hybrid Fc comprising a hinge region, a CH2 domain, and a CH3 domain, wherein the hinge region comprises a human IgD hinge region, the CD2 domain comprises a portion of a human IgD CH2 domain and a portion of a human IgG4 CH2 domain, and the CH3 domain comprises a portion of a human IgG4 CH3 domain.

[0017] In some embodiments, the IL-7 protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to SEQ ID NOs:1-6 and 15-25.

[0018] In some embodiments, the PD-1 pathway inhibitor that can be used in the methods of the invention comprises an anti-PD-1 antibody or an anti-PD-L1 antibody. In certain embodiments, the anti-PD-1 antibody comprises nivolumab, pembrolizumab, MEDI0608, AMP-224, PDR001, BGB-A317, or any combination thereof. In some embodiments, the anti-PD-L1 antibody comprises BMS-936559, MPDL3280A, MEDI4736, MSB0010718C, or any combination thereof.

[0019] In some embodiments, the IL-7 protein and the PD-1 pathway inhibitor are administered simultaneously. In other embodiments, the IL-7 protein and the PD-1 pathway inhibitor are administered sequentially. In certain embodiments, the IL-7 protein is administered to the subject prior to administration of the PD-1 pathway inhibitor.

[0020] In some embodiments, the tumor is derived from cancer including breast cancer, head and neck cancer, uterine cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, kidney cancer, pancreatic cancer, thyroid cancer, esophageal cancer, eye cancer, stomach cancer (gastric cancer), gastrointestinal cancer, ovarian cancer, carcinoma, sarcoma, leukemia, lymphoma, myeloma, or combinations thereof. In certain embodiments, the breast cancer is triple-negative breast cancer (TNBC). In certain embodiments, the brain cancer is glioblastoma. In some embodiments, the skin cancer is basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), melanoma, Merkel cell carcinoma (MCC), or combinations thereof. In further embodiments, the head and neck cancer is head and neck squamous cell carcinoma. In some embodiments, the lung cancer is small cell lung cancer (SCLC). In certain embodiments, the esophageal cancer is esophagogastric junction cancer. In some embodiments, the kidney cancer is renal cell carcinoma. In some embodiments, the liver cancer is hepatocellular carcinoma.

[0021] In some embodiments, the IL-7 protein is administered to the subject supplementally, intramuscularly, subcutaneously, by eye drop, intravenously, intraperitoneally, intradermally, intraorbitally, intracerebrally, intracranially, intraspinally, intraventricularly, intrathecally, intracisternally, intracapsularly, or intratumorally.

[0022] In some embodiments, the PD-1 pathway inhibitor is administered to the subject supplementally, intramuscularly, subcutaneously, intravenously, or intraperitoneally.

[0023] Also provided herein is a method for treating a tumor in a subject in need thereof, comprising administering to a human subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of a CTLA-4 pathway inhibitor. In certain embodiments, the tumor volume is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% after administration. In some embodiments, the human subject exhibits lymphopenia before administration.

[0024] In some embodiments, the CTLA-4 pathway inhibitor comprises an anti-CTLA-4 antibody. In certain embodiments, the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab (ticilimumab; CP-675,206), AGEN-1884, or a combination thereof.

[0025] In some embodiments, the IL-7 protein and the CTLA-4 pathway inhibitor are administered simultaneously. In other embodiments, the IL-7 protein and the CTLA-4 pathway inhibitor are administered sequentially. In certain embodiments, the IL-7 protein is administered to the subject prior to administration of the CTLA-4 pathway inhibitor.

[0026] In some embodiments, the tumor is derived from cancer, including breast cancer, head and neck cancer, uterine cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, renal cancer, pancreatic cancer, thyroid cancer, esophageal cancer, eye cancer, stomach cancer (gastric cancer), gastrointestinal cancer, ovarian cancer, carcinoma, sarcoma, leukemia, lymphoma, myeloma, or a combination thereof.

[0027] In some embodiments, the IL-7 protein of the disclosure is administered at a dose of greater than about 600 μg / kg, greater than about 700 μg / kg, greater than about 800 μg / kg, greater than about 900 μg / kg, greater than about 1,000 μg / kg, greater than about 1,100 μg / kg, greater than about 1,200 μg / kg, greater than about 1,300 μg / kg, greater than about 1,400 μg / kg, greater than about 1,500 μg / kg, greater than about 1,600 μg / kg, greater than about 1,700 μg / kg, greater than about 1,800 μg / kg, greater than about 1,900 μg / kg, or greater than about 2,000 μg / kg.

[0028] In some embodiments, the IL-7 protein is about 610 μg / kg to about 1,200 μg / kg, about 650 μg / kg to about 1,200 μg / kg, about 700 μg / kg to about 1,200 μg / kg, about 750 μg / kg to about 1,200 μg / kg, about 800 μg / kg to about 1,200 μg / kg, about 850 μg / kg to about 1,200 μg / kg, about 900 μg / kg to about 1,200 μg / kg, about 950 μg / kg to about 1,200 μg / kg, about 1,000 μg / kg to about 1,200 μg / kg, about 1,050 μg / kg to about 1,200 μg / kg, about 1,100 μg / kg to about 1,200 μg / kg, about 1,200 μg / kg, about 1,200 μg / kg, about 1,300 μg / kg, about 1,400 μg / kg, about 1,500 μg / kg, about 1,600 μg / kg, about 1,700 μg / kg, about 1,800 μg / kg, about 1,900 μg / kg, about 1,100 μg / kg, about 1,200 μg / kg, about 1,200 μg / kg, about 1,300 μg / kg, about 1,400 μg / kg, about 1,500 μg / kg, about 1,600 μg / kg, about 1,700 μg / kg, about 1,800 μg / kg, about 1,900 μg / kg, about 1,200 μg / kg, about 1,200 μg / kg, μg / kg ~ approx. 2,000 μg / kg, approx. 1,300 μg / kg ~ approx. 2,000 μg / kg, approx. 1,500 μg / kg ~ approx. 2,000 μg / kg, approx. 1, 700μg / kg ~ approx. 2,000μg / kg, approx. 610μg / kg ~ approx. 1,000μg / kg, approx. 650μg / kg ~ approx. 1,000μg / kg, approx. 700μ The therapeutic agent is administered at a dose of about 750 μg / kg to about 1,000 μg / kg, about 800 μg / kg to about 1,000 μg / kg, about 850 μg / kg to about 1,000 μg / kg, about 900 μg / kg to about 1,000 μg / kg, or about 950 μg / kg to about 1,000 μg / kg.

[0029] In some embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg to about 900 μg / kg, about 750 μg / kg to about 950 μg / kg, about 700 μg / kg to about 850 μg / kg, about 750 μg / kg to about 850 μg / kg, about 700 μg / kg to about 800 μg / kg, about 800 μg / kg to about 900 μg / kg, about 750 μg / kg to about 850 μg / kg, or about 850 μg / kg to about 950 μg / kg.

[0030] In some embodiments, the IL-7 protein is about 650 μg / kg, about 680 μg / kg, about 700 μg / kg, about 720 μg / kg, about 740 μg / kg, about 750 μg / kg, about 760 μg / kg, about 780 μg / kg, about 800 μg / kg, about 820 μg / kg, about 840 μg / kg, about 850 μg / kg, about 860 μg / kg, about 880 μg / kg, about 900 μg / kg, about 920 μg / kg, about 940 μg / kg, about 950 μg / kg / kg, approximately 960μg / kg, approximately 980μg / kg, approximately 1,000μg / kg, approximately 1,020μg / kg, approximately 1,040μg / kg, approximately 1,060μg / kg, approximately 1,080μg / kg, approximately 1,100μg / kg, approximately 1,2 00μg / kg, approximately 1,220μg / kg, approximately 1,240μg / kg, approximately 1,260μg / kg, approximately 1,280μg / kg, approximately 1,300μg / kg, approximately 1,320μg / kg, approximately 1,340μg / kg, approximately 1,360μg / kg, approximately 1,380μg / kg, approximately 1,400μg / kg, approximately 1,420μg / kg, approximately 1,440μg / kg, approximately 1,460μg / kg, approximately 1,480μg / kg, approximately 1,500μg / kg, approximately 1,520μg / kg, Approximately 1,540μg / kg, approximately 1,560μg / kg, approximately 1,580μg / kg, approximately 1,600μg / kg, approximately 1,620μg / kg, approximately 1,640μg / kg, approximately 1,660μg / kg, approximately 1,680μg / kg, approximately 1,7 In some embodiments, the antibody is administered at a dose of about 1,000 μg / kg, about 1,720 μg / kg, about 1,740 μg / kg, about 1,760 μg / kg, about 1,780 μg / kg, about 1,800 μg / kg, about 1,820 μg / kg, about 1,840 μg / kg, about 1,860 μg / kg, about 1,880 μg / kg, about 1,900 μg / kg, about 1,920 μg / kg, about 1,940 μg / kg, about 1,960 μg / kg, about 1,980 μg / kg, or about 2,000 μg / kg.

[0031] In some embodiments, the IL-7 protein is administered at a dosing frequency of once per week, once per 2 weeks, once per 3 weeks, once per 4 weeks, once per 5 weeks, once per 6 weeks, once per 7 weeks, once per 8 weeks, once per 9 weeks, once per 10 weeks, once per 11 weeks, or once per 12 weeks.

[0032] In some embodiments, the IL-7 protein is administered supplementally, hi some embodiments, the IL-7 protein is administered intravenously.

[0033] In some embodiments, the IL-7 protein, the PD-1 pathway inhibitor, and / or the CTLA-4 pathway inhibitor are formulated in a composition comprising a bulking agent, a stabilizer, a surfactant, a buffer, or a combination thereof.

[0034] In some embodiments, the PD-1 pathway inhibitor is nivolumab and the composition comprises (a) mannitol (e.g., about 30 mg), (b) pentetic acid (e.g., about 0.008 mg), (c) polysorbate 80 (e.g., about 0.2 mg), (d) sodium chloride (e.g., about 2.92 mg), and (e) anhydrous sodium citrate (e.g., about 5.88 mg). In certain embodiments, the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 240 mg every two weeks or about 480 mg every four weeks. In some embodiments, the PD-1 pathway inhibitor is administered to the subject at a weight basis dose of about 3 mg / kg every two weeks.

[0035] In some embodiments, the PD-1 pathway inhibitor is pembrolizumab and the composition comprises (a) L-histidine (e.g., about 1.55 mg), (b) polysorbate 80 (e.g., about 0.2 mg), and (c) sucrose (e.g., about 70 mg). In certain embodiments, the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 200 mg every three weeks. In further embodiments, the PD-1 pathway inhibitor is administered to the subject at a weight basis dose of about 2 mg / kg every three weeks.

[0036] In some embodiments, the PD-1 pathway inhibitor is atezolizumab and the composition comprises (a) glacial acetic acid (e.g., about 16.5 mg), (b) L-histidine (e.g., about 62 mg), (c) sucrose (e.g., about 821.6 mg), and (d) polysorbate 20 (e.g., about 8 mg). In certain embodiments, the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 1200 mg every three weeks.

[0037] In some embodiments, the PD-1 pathway inhibitor is durvalumab and the composition comprises (a) L-histidine (e.g., about 2 mg), (b) L-histidine hydrochloride monohydrate (e.g., about 2.7 mg), (c) α,α-trehalose dihydrate (e.g., about 104 mg), and (d) polysorbate 80 (e.g., about 0.2 mg). In certain embodiments, the PD-1 pathway inhibitor is administered to the subject at a weight basis dose of about 10 mg / kg every two weeks.

[0038] In some embodiments, the PD-1 pathway inhibitor is avelumab and the composition comprises (a) D-mannitol (e.g., about 51 mg), (b) glacial acetic acid (e.g., about 0.6 mg), (c) polysorbate 20 (e.g., about 0.5 mg), and (d) sodium hydroxide (e.g., about 0.3 mg). In some embodiments, the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 800 mg every two weeks.

[0039] In some embodiments, the CTLA-4 pathway inhibitor is ipilimumab and the composition comprises (a) diethylenetriaminepentaacetic acid (DTPA) (e.g., about 0.04 mg), (b) mannitol (e.g., about 10 mg), (c) polysorbate 80 (plant derived) (e.g., about 0.1 mg), (d) sodium chloride (e.g., about 5.85 mg), and (e) tris hydrochloride (e.g., about 3.15 mg). In certain embodiments, the CTLA-4 pathway inhibitor is administered to the subject at a weight basis dose of about 3 mg / kg every 3 weeks. In further embodiments, the CTLA-4 pathway inhibitor is administered to the subject at a weight basis dose of about 10 mg / kg every 3 weeks for 4 doses, followed by 10 mg / kg every 12 weeks.

[0040] In some embodiments, the IL-7 protein disclosed herein is formulated in a composition comprising (a) sodium citrate (e.g., about 20 mM), (b) sucrose (e.g., about 5%), (c) sorbitol (e.g., about 1.5%), and (d) Tween 80 (e.g., about 0.05%). In certain embodiments, for example, the following are provided: (Item 1) 1. A method of treating a tumor in a human subject in need of treatment comprising administering to said subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of a Programmed Death-1 (PD-1) pathway inhibitor, wherein tumor volume is reduced in said subject following said administration compared to a reference tumor volume following administration of either the PD-1 pathway inhibitor alone or the IL-7 protein alone. (Item 2) 2. The method of item 1, wherein the tumor volume is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% after said administration. (Item 3) 3. The method of item 1 or 2, wherein the number of tumor infiltrating lymphocytes (TILs) in the tumor is increased after said administering, as compared to the number of TILs in the tumor after administration of either the PD-1 pathway inhibitor alone or the IL-7 protein alone. (Item 4) The TIL is CD4 + The method according to item 3, wherein the TIL is a TIL. (Item 5) The TIL is CD8 + The method according to item 3, wherein the TIL is a TIL. (Item 6) 6. The method of any one of items 3-5, wherein the number of TILs is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after said administration. (Item 7) 7. The method according to any one of items 1 to 6, wherein the human subject exhibits lymphopenia prior to said administering. (Item 8) 1. A method of treating a tumor in a subject in need of treatment comprising administering to the subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of a Programmed Death-1 (PD-1) pathway inhibitor, wherein the subject exhibits lymphopenia. (Item 9) 9. The method of claim 7 or 8, wherein the human subject exhibiting lymphopenia has T lymphopenia, B lymphopenia, and / or NK lymphopenia. (Item 10) 10. The method according to any one of items 7 to 9, wherein the lymphopenia is caused by or associated with the tumor. (Item 11) 11. The method according to any one of items 7 to 10, wherein the lymphopenia is caused by or associated with a previous therapy for the tumor. (Item 12) 12. The method according to any one of items 7 to 11, wherein the lymphopenia is due to infection, chronic right ventricular failure, Hodgkin's disease and cancers of the lymphatic system, leukemia, leakage or rupture of the thoracic duct, side effects of prescription drugs including anti-cancer drugs (e.g. chemotherapy), anti-viral drugs, and glucocorticoids, malnutrition caused by a low protein diet, radiation therapy, uremia, autoimmune disorders, immune deficiency syndromes, high stress levels, trauma, thymectomy, or a combination thereof. (Item 13) 13. The method according to any one of items 7 to 12, wherein the lymphopenia is idiopathic. (Item 14) 14. The method of any one of items 7 to 13, wherein the lymphopenia comprises idiopathic CD4 positive T lymphopenia (ICL), acute radiation syndrome (ARS), or a combination thereof. (Item 15) 15. The method of any one of items 7 to 14, wherein the lymphopenia is characterized by a circulating total lymphocyte count that is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% lower compared to the total circulating lymphocyte count of a corresponding subject not exhibiting lymphopenia. (Item 16) 16. The method of any one of items 7 to 15, wherein the lymphopenia is characterized by a circulating total lymphocyte count of less than about 1,500 lymphocytes per μL, less than about 1,000 lymphocytes per μL, less than about 800 lymphocytes per μL, less than about 500 lymphocytes per μL, or less than about 200 lymphocytes per μL. (Item 17) 17. The method of any one of items 8-16, wherein the number of tumor infiltrating lymphocytes (TILs) in the tumor is increased after said administration compared to the number of TILs in the tumor after administration of either the PD-1 pathway inhibitor alone or the IL-7 protein alone. (Item 18) 20. The method of claim 17, wherein the number of TILs is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after the administration. (Item 19) The TIL is CD4 + 19. The method according to item 17 or 18, wherein the TIL. (Item 20) The TIL is CD8 + 19. The method according to item 17 or 18, wherein the TIL. (Item 21) 21. The method according to any one of items 1 to 20, wherein the IL-7 protein is not wild-type IL-7. (Item 22) 22. The method according to any one of items 1 to 21, wherein the IL-7 protein comprises an oligopeptide consisting of 1 to 10 amino acid residues. (Item 23) 23. The method of claim 22, wherein the oligopeptide is selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, and glycine-glycine-glycine. (Item 24) 24. The method of claim 23, wherein the oligopeptide is methionine-glycine-methionine. (Item 25) 25. The method of any one of items 1 to 24, wherein the IL-7 protein comprises a half-life extending moiety. (Item 26) 26. The method of claim 25, wherein the half-life extending moiety comprises Fc, albumin, albumin binding polypeptide, Pro / Ala / Ser (PAS), the C-terminal peptide of the beta subunit of human chorionic gonadotropin (CTP), polyethylene glycol (PEG), long unstructured hydrophilic amino acid sequences (XTEN), hydroxyethyl starch (HES), an albumin binding small molecule, or a combination thereof. (Item 27) 27. The method of item 26, wherein the half-life extending moiety is Fc. (Item 28) the Fc is a hybrid Fc comprising a hinge region, a CH2 domain, and a CH3 domain; the hinge region comprises a human IgD hinge region; the CH2 domain comprises a portion of a human IgD CH2 domain and a portion of a human IgG4 CH2 domain; 28. The method of claim 27, wherein the CH3 domain comprises a portion of a human IgG4 CH3 domain. (Item 29) 29. The method according to any one of Items 1 to 28, wherein the IL-7 protein comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to SEQ ID NOs: 1 to 6 and 15 to 25. (Item 30) 30. The method of any one of items 1 to 29, wherein the PD-1 pathway inhibitor comprises an anti-PD-1 antibody or an anti-PD-L1 antibody. (Item 31) 31. The method of item 30, wherein the anti-PD-1 antibody comprises nivolumab, pembrolizumab, MEDI0608, AMP-224, PDR001, BGB-A317, or any combination thereof. (Item 32) 32. The method of item 31, wherein the anti-PD-L1 antibody comprises BMS-936559, MPDL3280A, MEDI4736, MSB0010718C, or any combination thereof. (Item 33) 33. The method of any one of items 1 to 32, wherein the IL-7 protein and the PD-1 pathway inhibitor are administered simultaneously. (Item 34) 33. The method of any one of items 1 to 32, wherein the IL-7 protein and the PD-1 pathway inhibitor are administered sequentially. (Item 35) 35. The method of claim 34, wherein the IL-7 protein is administered to the subject prior to administering the PD-1 pathway inhibitor. (Item 36) 36. The method according to any one of items 1 to 35, wherein the tumor is derived from a cancer comprising breast cancer, head and neck cancer, uterine cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, renal cancer, pancreatic cancer, thyroid cancer, esophageal cancer, eye cancer, stomach cancer (gastric cancer), gastrointestinal cancer, ovarian cancer, carcinoma, sarcoma, leukemia, lymphoma, myeloma, or a combination thereof. (Item 37) 37. The method of claim 36, wherein the breast cancer is triple-negative breast cancer (TNBC). (Item 38) 37. The method of claim 36, wherein the brain cancer is glioblastoma. (Item 39) 37. The method of claim 36, wherein the skin cancer is basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), melanoma, Merkel cell carcinoma (MCC), or a combination thereof. (Item 40) 37. The method of claim 36, wherein the head and neck cancer is head and neck squamous cell carcinoma. (Item 41) 37. The method of claim 36, wherein the lung cancer is small cell lung cancer (SCLC). (Item 42) 37. The method of claim 36, wherein the esophageal cancer is gastroesophageal junction cancer. (Item 43) 37. The method of claim 36, wherein the kidney cancer is renal cell carcinoma. (Item 44) 37. The method of claim 36, wherein the liver cancer is hepatocellular carcinoma. (Item 45) 45. The method according to any one of items 1 to 44, wherein the IL-7 protein is administered to the subject supplementally, intramuscularly, subcutaneously, by eye drop, intravenously, intraperitoneally, intradermally, intraorbitally, intracerebrally, intracranially, intraspinally, intraventricularly, intrathecally, intracisternally, intracapsularly, or intratumorally. (Item 46) 46. ​​The method of any one of items 1-45, wherein the PD-1 pathway inhibitor is administered to the subject supplementally, intramuscularly, subcutaneously, intravenously, or intraperitoneally. (Item 47) A method of treating a tumor in a human subject in need of such treatment, comprising administering to the subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of a CTLA-4 pathway inhibitor. (Item 48) 48. The method of item 47, wherein the tumor volume is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% after said administration. (Item 49) 49. The method of claim 47 or 48, wherein the human subject exhibits lymphopenia prior to said administering. (Item 50) 50. The method of any one of items 47 to 49, wherein the CTLA-4 pathway inhibitor comprises an anti-CTLA-4 antibody. (Item 51) 51. The method of item 50, wherein the anti-CTLA-4 antibody comprises ipilimumab, tremelimumab (ticilimumab; CP-675,206), AGEN-1884, or a combination thereof. (Item 52) 52. The method of any one of items 47 to 51, wherein the IL-7 protein and the CTLA-4 pathway inhibitor are administered simultaneously. (Item 53) 52. The method of any one of items 47 to 51, wherein the IL-7 protein and the CTLA-4 pathway inhibitor are administered sequentially. (Item 54) 54. The method of claim 53, wherein the IL-7 protein is administered to the subject prior to administering the CTLA-4 pathway inhibitor. (Item 55) 55. The method according to any one of items 47 to 54, wherein the tumor is derived from a cancer comprising breast cancer, head and neck cancer, uterine cancer, brain cancer, skin cancer, renal cancer, lung cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, kidney cancer, pancreatic cancer, thyroid cancer, esophageal cancer, eye cancer, stomach cancer (gastric cancer), gastrointestinal cancer, ovarian cancer, carcinoma, sarcoma, leukemia, lymphoma, myeloma, or a combination thereof. (Item 56) 56. The method of any one of items 1-55, wherein the IL-7 protein is administered at a dose of greater than about 600 μg / kg, greater than about 700 μg / kg, greater than about 800 μg / kg, greater than about 900 μg / kg, greater than about 1,000 μg / kg, greater than about 1,100 μg / kg, greater than about 1,200 μg / kg, greater than about 1,300 μg / kg, greater than about 1,400 μg / kg, greater than about 1,500 μg / kg, greater than about 1,600 μg / kg, greater than about 1,700 μg / kg, greater than about 1,800 μg / kg, greater than about 1,900 μg / kg, or greater than about 2,000 μg / kg. (Item 57) The IL-7 protein is about 610 μg / kg to about 1,200 μg / kg, about 650 μg / kg to about 1,200 μg / kg, about 700 μg / kg to about 1,200 μg / kg, about 750 μg / kg to about 1,200 μg / kg, about 800 μg / kg to about 1,200 μg / kg, about 850 μg / kg to about 1,200 μg / kg, approximately 900μg / kg to approximately 1,200μg / kg, approximately 950μg / kg to approximately 1,200μg / kg, approximately 1,000μg / kg to approximately 1,200μg / k g, approximately 1,050μg / kg to approximately 1,200μg / kg, approximately 1,100μg / kg to approximately 1,200μg / kg, approximately 1,200μg / kg to approximately 2,000μg / 57. The method according to any one of items 1 to 56, wherein the patient is administered at a dose of about 1,300 μg / kg to about 2,000 μg / kg, about 1,500 μg / kg to about 2,000 μg / kg, about 1,700 μg / kg to about 2,000 μg / kg, about 610 μg / kg to about 1,000 μg / kg, about 650 μg / kg to about 1,000 μg / kg, about 700 μg / kg to about 1,000 μg / kg, about 750 μg / kg to about 1,000 μg / kg, about 800 μg / kg to about 1,000 μg / kg, about 850 μg / kg to about 1,000 μg / kg, about 900 μg / kg to about 1,000 μg / kg, or about 950 μg / kg to about 1,000 μg / kg. (Item 58) 58. The method according to any one of items 1 to 57, wherein the IL-7 protein is administered at a dose of about 700 μg / kg to about 900 μg / kg, about 750 μg / kg to about 950 μg / kg, about 700 μg / kg to about 850 μg / kg, about 750 μg / kg to about 850 μg / kg, about 700 μg / kg to about 800 μg / kg, about 800 μg / kg to about 900 μg / kg, about 750 μg / kg to about 850 μg / kg, or about 850 μg / kg to about 950 μg / kg. (Item 59) The IL-7 protein is about 650 μg / kg, about 680 μg / kg, about 700 μg / kg, about 720 μg / kg, about 740 μg / kg, about 750 μg / kg, about 760 μg / kg, about 780 μg / kg, about 800 μg / kg, about 820 μg / kg, about 840 μg / kg, about 850 μg / kg, about 860 μg / kg, about 880 μg / kg, about 900 μg / kg, about 920 μg / kg, about 940 μg / kg, about 950 μg / kg, about 960 μg / kg, about 980 μg / kg, 1,000μg / kg, approximately 1,020μg / kg, approximately 1,040μg / kg, approximately 1,060μg / kg, approximately 1,080μg / kg, approximately 1,100μg / kg, approximately 1,120μg / kg, approximately 1,140μg / kg, approximately 1,160μg / kg, Approximately 1,180μg / kg, approximately 1,200μg / kg, approximately 1,220μg / kg, approximately 1,240μg / kg, approximately 1,260μg / kg, approximately 1,280μg / kg, approximately 1,300μg / kg, approximately 1,320μg / kg, approximately 1,340μg / kg , about 1,360μg / kg, about 1,380μg / kg, about 1,400μg / kg, about 1,420μg / kg, about 1,440μg / kg, about 1,460μg / kg, about 1,480μg / kg, about 1,500μg / kg, about 1,520μg / k g, approximately 1,540μg / kg, approximately 1,560μg / kg, approximately 1,580μg / kg, approximately 1,600μg / kg, approximately 1,620μg / kg, approximately 1,640μg / kg, approximately 1,660μg / kg, approximately 1,680μg / kg, approximately 1,700μg / 59. The method of any one of items 1-58, wherein the patient is administered at a dose of about 1,720 μg / kg, about 1,740 μg / kg, about 1,760 μg / kg, about 1,780 μg / kg, about 1,800 μg / kg, about 1,820 μg / kg, about 1,840 μg / kg, about 1,860 μg / kg, about 1,880 μg / kg, about 1,900 μg / kg, about 1,920 μg / kg, about 1,940 μg / kg, about 1,960 μg / kg, about 1,980 μg / kg, or about 2,000 μg / kg. (Item 60) 60. The method of any one of items 1 to 59, wherein the IL-7 protein is administered at a dosing frequency of once per week, once per 2 weeks, once per 3 weeks, once per 4 weeks, once per 5 weeks, once per 6 weeks, once per 7 weeks, once per 8 weeks, once per 9 weeks, once per 10 weeks, once per 11 weeks, or once per 12 weeks. (Item 61) 61. The method according to any one of items 1 to 60, wherein the IL-7 protein is administered supplementally. (Item 62) 61. The method according to any one of items 1 to 60, wherein the IL-7 protein is administered intravenously. (Item 63) 63. The method of any one of items 1-62, wherein the IL-7 protein, the PD-1 pathway inhibitor, and / or the CTLA-4 pathway inhibitor are formulated in a composition comprising a bulking agent, a stabilizer, a surfactant, a buffer, or a combination thereof. (Item 64) 64. The method of claim 63, wherein the PD-1 pathway inhibitor is nivolumab and the composition comprises (a) mannitol (e.g., about 30 mg), (b) pentetic acid (e.g., about 0.008 mg), (c) polysorbate 80 (e.g., about 0.2 mg), (d) sodium chloride (e.g., about 2.92 mg), and (e) anhydrous sodium citrate (e.g., about 5.88 mg). (Item 65) 65. The method of item 64, wherein the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 240 mg every two weeks or about 480 mg every four weeks. (Item 66) 65. The method of claim 64, wherein the PD-1 pathway inhibitor is administered to the subject at a weight basis dose of about 3 mg / kg every two weeks. (Item 67) 64. The method of claim 63, wherein the PD-1 pathway inhibitor is pembrolizumab and the composition comprises (a) L-histidine (e.g., about 1.55 mg), (b) polysorbate 80 (e.g., about 0.2 mg), and (c) sucrose (e.g., about 70 mg). (Item 68) 68. The method of claim 67, wherein the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 200 mg every three weeks. (Item 69) 68. The method of claim 67, wherein the PD-1 pathway inhibitor is administered to the subject at a weight basis dose of about 2 mg / kg every 3 weeks. (Item 70) 64. The method of claim 63, wherein the PD-1 pathway inhibitor is atezolizumab and the composition comprises (a) glacial acetic acid (e.g., about 16.5 mg), (b) L-histidine (e.g., about 62 mg), (c) sucrose (e.g., about 821.6 mg), and (d) polysorbate 20 (e.g., about 8 mg). (Item 71) 71. The method of claim 70, wherein the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 1200 mg every three weeks. (Item 72) 64. The method of claim 63, wherein the PD-1 pathway inhibitor is durvalumab and the composition comprises (a) L-histidine (e.g., about 2 mg), (b) L-histidine hydrochloride monohydrate (e.g., about 2.7 mg), (c) α,α-trehalose dihydrate (e.g., about 104 mg), and (d) polysorbate 80 (e.g., about 0.2 mg). (Item 73) 73. The method of claim 72, wherein the PD-1 pathway inhibitor is administered to the subject at a weight basis dose of about 10 mg / kg every two weeks. (Item 74) 64. The method of claim 63, wherein the PD-1 pathway inhibitor is avelumab and the composition comprises (a) D-mannitol (e.g., about 51 mg), (b) glacial acetic acid (e.g., about 0.6 mg), (c) polysorbate 20 (e.g., about 0.5 mg), and (d) sodium hydroxide (e.g., about 0.3 mg). (Item 75) 75. The method of claim 74, wherein the PD-1 pathway inhibitor is administered to the subject at a fixed dose of about 800 mg every two weeks. (Item 76) 64. The method of claim 63, wherein the CTLA-4 pathway inhibitor is ipilimumab and the composition comprises (a) diethylenetriaminepentaacetic acid (DTPA) (e.g., about 0.04 mg), (b) mannitol (e.g., about 10 mg), (c) polysorbate 80 (vegetable derived) (e.g., about 0.1 mg), (d) sodium chloride (e.g., about 5.85 mg), and (e) tris hydrochloride (e.g., about 3.15 mg). (Item 77) 77. The method of claim 76, wherein the CTLA-4 pathway inhibitor is administered to the subject at a weight basis dose of about 3 mg / kg every three weeks. (Item 78) The method of claim 76, wherein the CTLA-4 pathway inhibitor is administered to the subject at about 10 mg / kg every 3 weeks for 4 doses, followed by a weight basis dose of 10 mg / kg every 12 weeks. 79. The method of any one of items 63 to 78, wherein the IL-7 protein is formulated in a composition comprising (a) sodium citrate (e.g., about 20 mM), (b) sucrose (e.g., about 5%), (c) sorbitol (e.g., about 1.5%), and (d) Tween 80 (e.g., about 0.05%). [Brief description of the drawings]

[0041] [Figure 1] Figures A, B, and C show the effect of administration of IL-7 protein and anti-PD-1 antibody on tumor volume in a mouse adenocarcinoma model. Figure A shows the schedule of tumor seeding and treatment administration. Figures B and C provide a comparison of tumor volume (mm3) for each treatment group in two different studies, respectively. Treatment groups included: (1) IL-7 formulation buffer + isotype control antibody (circle), (2) IL-7 formulation buffer + anti-PD-1 antibody (triangle), (3) IL-7 protein + isotype control antibody (inverted triangle), and (4) IL-7 protein + anti-PD-1 antibody (diamond). Data are presented as mean ± SEM. All comparisons were made using two-way ANOVA with Bonferroni post-hoc test. "*" and "***" indicate statistically significant differences compared to control animals (p<0.05 and p<0.0001, respectively). [Diagram 2] A, B, and C show the effect of administration of IL-7 protein and anti-PD-1 antibody on the number of tumor infiltrating lymphocytes (TILs) in animals in each treatment group. A shows the schedule of tumor inoculation and treatment administration. B presents a comparison of the number of CD4+ TILs in each treatment group. C presents a comparison of the number of CD8+ TILs in each treatment group. Treatment groups included: (1) IL-7 formulation buffer + isotype control antibody, (2) IL-7 formulation buffer + anti-PD-1 antibody, (3) IL-7 protein + isotype control antibody, and (4) IL-7 protein + anti-PD-1 antibody. In both B and C, the number of CD4+ TILs and CD8+ TILs are shown as a percentage of total CD45+ cells in the tumor. Data are shown for individual animals and as mean ± SEM. All comparisons were made using one-way ANOVA with Tukey's multiple comparison test. "*", "**", and "***" indicate statistically significant differences compared to control animals (p<0.05, p<0.01, and p<0.0001, respectively). [Figure 3A] Figures A, B, and C show the effect of the triple combination of cyclophosphamide (CPA), IL-7 protein, and PD-1 pathway inhibitor on the tumor volume and survival time of animals in each treatment group. Figure 3A shows the schedule of tumor seeding and treatment administration. Figure 3B shows a comparison of tumor volume (mm3) of each treatment group at various time points after CPA treatment. Figure 3C shows survival time data. Treatment groups included: (1) PBS + IL-7 formulation buffer + isotype control antibody, (2) CPA + IL-7 formulation buffer + isotype control antibody, (3) CPA + IL-7 protein + isotype control antibody, (4) CPA + IL-7 protein + anti-PD-1 antibody, and (5) CPA + IL-7 protein + anti-PD-L1 antibody. In Figure 3B, data are shown as mean ± SEM. Comparisons of each treatment group were performed using two-way ANOVA with Bonferroni post-hoc test. "*" and "***" indicate statistically significant differences compared to control animals (p<0.05 and p<0.001, respectively). [Figure 3B]Figures A, B, and C show the effect of the triple combination of cyclophosphamide (CPA), IL-7 protein, and PD-1 pathway inhibitor on the tumor volume and survival time of animals in each treatment group. Figure 3A shows the schedule of tumor seeding and treatment administration. Figure 3B shows a comparison of tumor volume (mm3) of each treatment group at various time points after CPA treatment. Figure 3C shows survival time data. Treatment groups included: (1) PBS + IL-7 formulation buffer + isotype control antibody, (2) CPA + IL-7 formulation buffer + isotype control antibody, (3) CPA + IL-7 protein + isotype control antibody, (4) CPA + IL-7 protein + anti-PD-1 antibody, and (5) CPA + IL-7 protein + anti-PD-L1 antibody. In Figure 3B, data are shown as mean ± SEM. Comparisons of each treatment group were performed using two-way ANOVA with Bonferroni post-hoc test. "*" and "***" indicate statistically significant differences compared to control animals (p<0.05 and p<0.001, respectively). [Figure 3C] Figures A, B, and C show the effect of the triple combination of cyclophosphamide (CPA), IL-7 protein, and PD-1 pathway inhibitor on the tumor volume and survival time of animals in each treatment group. Figure 3A shows the schedule of tumor seeding and treatment administration. Figure 3B shows a comparison of tumor volume (mm3) of each treatment group at various time points after CPA treatment. Figure 3C shows survival time data. Treatment groups included: (1) PBS + IL-7 formulation buffer + isotype control antibody, (2) CPA + IL-7 formulation buffer + isotype control antibody, (3) CPA + IL-7 protein + isotype control antibody, (4) CPA + IL-7 protein + anti-PD-1 antibody, and (5) CPA + IL-7 protein + anti-PD-L1 antibody. In Figure 3B, data are shown as mean ± SEM. Comparisons of each treatment group were performed using two-way ANOVA with Bonferroni post-hoc test. "*" and "***" indicate statistically significant differences compared to control animals (p<0.05 and p<0.001, respectively). [Figure 4]A and B show the effect of administration of IL-7 protein and anti-PD-1 antibody on tumor volume in thymectomized animals. A is the study design. B presents a comparison of tumor volume (mm3) in each treatment group. Treatment groups included (1) IL-7 formulation buffer + isotype control antibody (circle), (2) IL-7 protein + isotype control antibody (square), (3) IL-7 formulation buffer + anti-PD-1 antibody (triangle), and (4) IL-7 protein + anti-PD-1 antibody (inverted triangle). Arrows indicate the time of administration of IL-7 protein (gray arrow) and anti-PD-1 antibody (black arrow). Data are presented as mean ± SEM. Comparisons of each treatment group were performed using two-way ANOVA with Bonferroni post-hoc test. "***" indicates statistically significant difference (p<0.001) compared to control animals. [Diagram 5] A, B, and C show the effect of administration of IL-7 protein and anti-PD-1 antibody on tumor infiltrating lymphocyte (TIL) counts in thymectomized animals. A is the study design. B and C present a comparison of CD4+ and CD8+ TIL counts, respectively. Treatment groups included: (1) IL-7 formulated buffer + isotype control antibody ("control"), (2) IL-7 formulated buffer + anti-PD-1 antibody ("α-PD1"), (3) IL-7 protein + isotype control antibody ("IL-7"), and (4) IL-7 protein + anti-PD-1 antibody ("combination"). In both B and C, CD4+ and CD8+ TIL counts are shown as a percentage of total CD45+ cells in the tumor. Data are shown for individual animals and as mean ± SEM. All comparisons were performed using one-way ANOVA with Tukey's multiple comparison test. "*", "**", and "***" indicate statistically significant differences compared to control animals (p<0.05, p<0.01, and p<0.0001, respectively). [Figure 6A]Figure 1 shows the effect of IL-7 protein on cytokine-induced T cell proliferation and activation in normal C57BL / 6 mice. Figure 2 shows the dynamics of CD8+ T cell subsets in blood after treatment with IL-7 protein. CD8+ T cell subsets shown include: (i) total CD8+ T cells (left graph), (ii) CD8+CD44- cells (middle graph), and (iii) CD8+CD44+ cells (right graph). The top row shows the number of CD8+ T cell subsets as a percentage of total white blood cells. The bottom row shows the percentage of CD8+ T cell subsets that are Ki67+ (i.e., actively proliferating). Control animals received buffer only (open circles). Data are shown as mean ± SD. [Figure 6B] Figure 1 shows the effect of IL-7 protein on cytokine-induced T cell proliferation and activation in normal C57BL / 6 mice. The expression profile (blue lines) of various activation markers in CD8+ splenic T cells 5 days after IL-7 protein administration is shown. The black line corresponds to the isotype control. Activation markers shown include (from left to right): T-bet, Eomes, PD-1, Granzyme B (GzmB), CXCR3, IFN-γ, TNF-α, and IL-2. [Figure 7] A, B, and C show the effect of administration of IL-7 protein on the activation and proliferation of mouse naive (top row) and central memory CD8+ T cells (bottom row). A shows the CD44 and CD62L expression profiles of splenic naive and central memory T cells 5 days after IL-7 administration. B and C present proliferation data (based on CTV staining and Ki67 expression, respectively). In B and C, blue represents T cells from animals that received IL-7 protein, while orange represents T cells from control animals (i.e., those that received buffer only). [Figure 8A]Figure 8 shows the dose-dependent antitumor effect of IL-7 protein administration in a syngeneic tumor model. Comparison of tumor volume (mm3) in animals receiving various concentrations of IL-7 protein: (i) 0 mg / kg (i.e., buffer only) (black), (ii) 1.25 mg / kg (orange), (iii) 2.5 mg / kg (green), (iv) 5 mg / kg (blue), (v) 10 mg / kg (red) are presented. *p<0.05, **p<0.01, ***p<0.001 versus the buffer group by two-way ANOVA with Bonferroni post-hoc test (Figure 8A) or one-way ANOVA with Dunnett post-hoc test (Figure 8C). Data are presented as mean ± SD. [Figure 8B] Figure 1 shows the dose-dependent antitumor effect of IL-7 protein administration in a syngeneic tumor model. The percentage of immune cell compartments among CD45+ cells in PBMCs 7 days after IL-7 protein administration is presented. Each immune cell compartment shown includes (i) CD8+ T cells (blue), (ii) CD4+ T cells (orange), (iii) Foxp3+CD4+ regulatory T cells (purple), (iv) B220+ B cells (gray), and (v) other immune cells that do not fall into any of the four aforementioned categories (white). Each column represents a different concentration of IL-7 protein. [Figure 8C] Figure 8 shows the dose-dependent antitumor effect of IL-7 protein administration in a syngeneic tumor model. Absolute numbers of different immune cell populations in PBMCs at day 7 after treatment are shown. Immune cell populations shown include (i) CD8+ T cells (first graph), (ii) CD4+ T cells (second graph), (iii) Foxp3+ regulatory T cells (third graph), and (iv) B220+ B cells (fourth graph). The x-axis presents the concentration of IL-7 protein administered to each treatment group. *p<0.05, **p<0.01, ***p<0.001 vs. buffer group by two-way ANOVA with Bonferroni post-hoc test (Figure 8A) or one-way ANOVA with Dunnett post-hoc test (Figure 8C). Data are presented as mean ± SD. [Figure 9A]We show that IL-7 protein can induce antitumor activity by inducing a CD8+ T cell inflammatory tumor microenvironment. We present the percentage (top graph) and number (bottom graph) of various tumor-infiltrating leukocytes (TILs) observed in tumors of mice 5 days after administration of IL-7 protein (purple) or buffer only (orange). Each TIL shown includes (i) monocytic myeloid-derived suppressor cells (M-MDSCs), (ii) polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), (iii) tumor-associated macrophages (TAMs), (iv) tumor-associated dendritic cells (TADCs), (v) CD8+ T cells, (vi) CD4+ helper T cells (CD4Th cells), (v) CD4+ regulatory T cells (Treg cells), (vi) NK cells, and (vii) B cells. In each of Figures 9A-9H, *p<0.05, **p<0.01, ***p<0.001 versus the buffer group by unpaired t-test. Data are presented as mean ± sd. [Figure 9B] We show that IL-7 protein can result in antitumor activity by inducing a CD8+ T cell inflammatory tumor microenvironment. Comparisons of the ratios of CD8+ TILs to Foxp3+ regulatory T cells (left graph) or MDSCs (right graph) at 5 days after treatment in animals treated with buffer only (orange) or IL-7 protein (purple) are presented. *p<0.05, **p<0.01, ***p<0.001 by unpaired t-test versus buffer group in each of Figures 9A-9H. Data are presented as mean ± sd. [Figure 9C] This shows that IL-7 protein can result in antitumor activity by inducing a CD8+ T cell inflammatory tumor microenvironment. Comparisons of the percentage of Ki67+ cells (left graph) or Granzyme B+ cells (right graph) in CD8+ TILs at day 5 after treatment in animals treated with buffer only (orange) or IL-7 protein (purple) are presented. *p<0.05, **p<0.01, ***p<0.001 by independent t-test versus buffer group in each of Figures 9A-9H. Data are presented as mean ± sd. [Figure 9D]Figure 9 shows that IL-7 protein can lead to antitumor activity by inducing a CD8+ T cell inflammatory tumor microenvironment. The percentage of IFN-γ and / or TNF-α producing CD8+ TILs in animals treated with buffer only (orange) or IL-7 protein (purple) at 5 days post-treatment is presented. *p<0.05, **p<0.01, ***p<0.001 by unpaired t-test vs. buffer group in each of Figures 9A-9H. Data are presented as mean ± sd. [Figure 9E] Figure 9 shows that IL-7 protein can induce CD8+ T cell inflammatory tumor microenvironment and thereby provide anti-tumor activity. The percentage of PD-1+ cells in CD8+ TILs from animals treated with buffer only or IL-7 protein is shown. *p<0.05, **p<0.01, ***p<0.001 by unpaired t-test versus buffer group in each of Figures 9A-9H. Data are presented as mean±sd. [Figure 9F] This shows that IL-7 protein can bring about anti-tumor activity by inducing a CD8+ T cell inflammatory tumor microenvironment. The percentage of LAG-3+TIM-3+ cells in CD8+PD-1+TILs is shown. In each of Figures 9A-9H, *p<0.05, **p<0.01, ***p<0.001 by independent t-test against the buffer group. Data are presented as mean ± sd. [Figure 9G] Figure 9 shows that IL-7 protein can lead to antitumor activity by inducing a CD8+ T cell inflammatory tumor microenvironment. Geometric mean fluorescence intensity (gMFI) of expression levels of various immune checkpoint receptors in PD-1+LAG-3+TIM-3+CD8+TILs from animals treated with buffer only or IL-7 protein is shown. *p<0.05, **p<0.01, ***p<0.001 by unpaired t-test versus buffer group in each of Figures 9A-9H. Data are presented as mean ± sd. [Figure 9H]This shows that IL-7 protein can lead to antitumor activity by inducing a CD8+ T cell inflammatory tumor microenvironment. The relative expression of various chemokines (CCL2, CCL5, CXCL1, CXCL9, CXCL10, and CXCL11) measured by RT-qPCR measurement in tumor lysates of animals treated with buffer (white) or IL-7 protein (green) is presented. *p<0.05, **p<0.01, ***p<0.001 by unpaired t-test versus buffer group in each of Figures 9A-9H. Data are presented as mean ± sd. [Figure 10] Figure 1 shows the anti-tumor effect of IL-7 protein in combination with cyclophosphamide (CPA) and / or immune checkpoint inhibitors. The graph on the left presents tumor volume (mm3) at various time points after treatment. The graph on the right presents survival data. The top row presents results for animals treated with (i) buffer only, (ii) a combination of CPA and an anti-PD-1 antibody, or (iii) a combination of CPA, an anti-PD-1 antibody, and an IL-7 protein. The middle row presents results for animals treated with (i) buffer only, (ii) a combination of CPA and an anti-PD-L1 antibody, or (iii) a combination of CPA, an anti-PD-L1 antibody, and an IL-7 protein. The bottom row presents results for animals treated with (i) buffer only, (ii) a combination of CPA and an anti-CTLA-4 antibody, or (iii) a combination of CPA, an anti-CTLA-4 antibody, and an IL-7 protein. **p<0.01, ***p<0.001 by log-rank (Mantel-Cox) test versus corresponding color groups in graph legend. Data are presented as mean ± sd. [Figure 11]A presents a comparison of CD8+ T cell counts in spleens, peripheral blood, and lymph nodes of thymectomized animals and sham controls. B shows the number of each CD8+ T cell population in the spleens of tumor-bearing mice treated with PBS or IL-7 protein at various weekly time points post-treatment. The CD8+ T cell populations shown include (i) total CD8+ T cells (first graph), (ii) naive (CD44-CD62L+) CD8+ T cells (second graph), (iii) effector memory (CD44+CD62L-) CD8+ T cells (third graph), and (iv) central memory (CD44+CD62L+) CD8+ T cells (fourth graph). *p<0.05, **p<0.01, ***p<0.001 by unpaired t-test between the groups shown. [Figure 12] FIG. 1 is a schematic diagram of the study design of the Phase 1b clinical trial described in Example 11 evaluating the safety and efficacy of IL-7 protein in patients with advanced solid tumors. [Figure 13] A table summarizing adverse effects observed in patients with advanced solid tumors in the Phase 1b clinical trial described in Example 11 is presented. "TEAE" means any treatment-emergent adverse event. "ADR" means adverse drug reaction. [Figure 14] A, B, and C present the pharmacokinetic analysis results of the Phase 1b clinical trial described in Example 11. A presents a comparison of IL-7 concentrations in serum of patients with advanced solid tumors treated with various doses of IL-7 protein. As described in Example 11, the doses included: (i) 60 μg / kg ("1"), (ii) 120 μg / kg ("2"), (iii) 240 μg / kg ("3"), (iv) 480 μg / kg ("4"), (v) 720 μg / kg ("5"), (vi) 960 μg / kg ("6"), and (vii) 1,200 μg / kg ("7"). B and C present a comparison of Cmax and AUC in patients with advanced solid tumors in each dose group. Data are presented as mean ± SEM for each dose level. [Figure 15A]Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 11 are presented. Figures 15A-15D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in patients with advanced solid cancers, respectively, before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose. Figures 15E and 15F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose groups (60 and 120 μg / kg) ("circles"), medium dose groups (240 and 480 μg / kg) ("squares"), and high dose groups (720 and 1,200 μg / kg) ("triangles"). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 15B] Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 11 are presented. Figures 15A-15D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in patients with advanced solid cancers, respectively, before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose. Figures 15E and 15F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose groups (60 and 120 μg / kg) ("circles"), medium dose groups (240 and 480 μg / kg) ("squares"), and high dose groups (720 and 1,200 μg / kg) ("triangles"). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 15C]Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 11 are presented. Figures 15A-15D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in patients with advanced solid cancers, respectively, before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose. Figures 15E and 15F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose groups (60 and 120 μg / kg) ("circles"), medium dose groups (240 and 480 μg / kg) ("squares"), and high dose groups (720 and 1,200 μg / kg) ("triangles"). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 15D] Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 11 are presented. Figures 15A-15D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in patients with advanced solid cancers, respectively, before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose. Figures 15E and 15F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose groups (60 and 120 μg / kg) ("circles"), medium dose groups (240 and 480 μg / kg) ("squares"), and high dose groups (720 and 1,200 μg / kg) ("triangles"). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 15E]Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 11 are presented. Figures 15A-15D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in patients with advanced solid cancers, respectively, before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose. Figures 15E and 15F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose groups (60 and 120 μg / kg) ("circles"), medium dose groups (240 and 480 μg / kg) ("squares"), and high dose groups (720 and 1,200 μg / kg) ("triangles"). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 15F] Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 11 are presented. Figures 15A-15D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in patients with advanced solid cancers, respectively, before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose. Figures 15E and 15F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose groups (60 and 120 μg / kg) ("circles"), medium dose groups (240 and 480 μg / kg) ("squares"), and high dose groups (720 and 1,200 μg / kg) ("triangles"). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16A]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16B]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16C]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16D]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16E]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16F]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16G]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 16H]A comparison of the effect of IL-7 protein administration on different CD4+ and CD8+ T cell subsets in patients from the Phase 1b clinical trial described in Example 11 is presented. Figures 16A and 16C present a comparison of Ki67+CD4+T cells and Ki67+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figures 16B and 16D present a comparison of CD127+CD4+T cells and CD127+CD8+T cells in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"), respectively. Figure 16E presents a comparison of CD4+T cell / Treg ratios (left graph) and CD8+T cell / Treg ratios (right graph) in patients before IL-7 protein administration (i.e., time point "0") and one week after administration (i.e., time point "1"). Figure 16F presents a comparison of naive (left column), effector memory (EM) (middle column), and central memory (CM) (right column) subsets for both CD4+ T cells (top row) and CD8+ T cells (bottom row) in patients prior to IL-7 protein administration (i.e., time "0") and 3 weeks after administration (i.e., time "3"). Figures 16G and 16H present a comparison of CCR5+CD4+T cells and CCR5+CD8+T cells, respectively, in patients prior to IL-7 protein administration (i.e., time "0") and 1 week after administration (i.e., time "1"). In each figure, patients were classified into low-dose groups (60 and 120 μg / kg) (circles; left two columns), medium-dose groups (240 and 480 μg / kg) (squares; center two columns), and high-dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed-rank test versus baseline (week 0) group, "**" means p<0.01, and "***" means p<0.001. [Figure 17]Figures A and B present a comparison of the effects of IL-7 protein administration on NK cells and B cells, respectively, before (i.e., time point "0") and 3 weeks after (i.e., time point "3") administration of IL-7 protein in patients from the Phase 1b clinical trial described in Example 11. In both figures, patients were classified into low dose groups (60 and 120 μg / kg) (circles; left two columns), medium dose groups (240 and 480 μg / kg) (squares; center two columns), and high dose groups (720 and 1,200 μg / kg) (triangles; right two columns). "*" means p<0.05 by Wilcoxon matched-pairs signed rank test versus baseline (week 0) group. [Figure 18] A table summarizing adverse effects observed in glioblastoma patients in the Phase 1b clinical trial described in Example 12 is presented. "TEAE" means any treatment-emergent adverse event. "ADR" means adverse drug reaction. [Figure 19A] Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 12 are presented. Figures 19A-19D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in glioblastoma cancer patients before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose, respectively. Figures 19E and 19F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose group (60 μg / kg) (circles), medium dose group (360 and 600 μg / kg) (squares), and high dose group (840 and 1,440 μg / kg) (triangles). "*" means p<0.05 and "**" means p<0.01 by Wilcoxon matched-pairs signed rank test versus baseline (week 0) group. [Figure 19B]Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 12 are presented. Figures 19A-19D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in glioblastoma cancer patients before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose, respectively. Figures 19E and 19F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose group (60 μg / kg) (circles), medium dose group (360 and 600 μg / kg) (squares), and high dose group (840 and 1,440 μg / kg) (triangles). "*" means p<0.05 and "**" means p<0.01 by Wilcoxon matched-pairs signed rank test versus baseline (week 0) group. [Figure 19C] Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 12 are presented. Figures 19A-19D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in glioblastoma cancer patients before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose, respectively. Figures 19E and 19F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose group (60 μg / kg) (circles), medium dose group (360 and 600 μg / kg) (squares), and high dose group (840 and 1,440 μg / kg) (triangles). "*" means p<0.05 and "**" means p<0.01 by Wilcoxon matched-pairs signed rank test versus baseline (week 0) group. [Figure 19D]Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 12 are presented. Figures 19A-19D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in glioblastoma cancer patients before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose, respectively. Figures 19E and 19F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose group (60 μg / kg) (circles), medium dose group (360 and 600 μg / kg) (squares), and high dose group (840 and 1,440 μg / kg) (triangles). "*" means p<0.05 and "**" means p<0.01 by Wilcoxon matched-pairs signed rank test versus baseline (week 0) group. [Figure 19E] Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 12 are presented. Figures 19A-19D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in glioblastoma cancer patients before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose, respectively. Figures 19E and 19F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose group (60 μg / kg) (circles), medium dose group (360 and 600 μg / kg) (squares), and high dose group (840 and 1,440 μg / kg) (triangles). "*" means p<0.05 and "**" means p<0.01 by Wilcoxon matched-pairs signed rank test versus baseline (week 0) group. [Figure 19F]Pharmacodynamic analysis results of the Phase 1b clinical trial described in Example 12 are presented. Figures 19A-19D present a comparison of absolute lymphocyte counts (ALC), CD3+ T cell counts, CD4+ T cell counts, and CD8+ T cell counts in glioblastoma cancer patients before IL-7 protein administration (i.e., time point "0") and 3 weeks after the first dose, respectively. Figures 19E and 19F present a comparison of ALC in non-lymphopenic and lymphopenic patients, respectively. In each figure, patients were classified into low dose group (60 μg / kg) (circles), medium dose group (360 and 600 μg / kg) (squares), and high dose group (840 and 1,440 μg / kg) (triangles). "*" means p<0.05 and "**" means p<0.01 by Wilcoxon matched-pairs signed rank test versus baseline (week 0) group. [Figure 20A] Figures A, B, and C show the effect of IL-7 protein administration on AUC, Ki67+CD8+ T cell frequency, and Ki67+CD4+ T cell frequency in glioblastoma patients receiving temozolomide (TMZ), respectively. In each figure, the days on which TMZ or IL-7 protein was administered are indicated. [Figure 20B] Figures A, B, and C show the effect of IL-7 protein administration on AUC, Ki67+CD8+ T cell frequency, and Ki67+CD4+ T cell frequency in glioblastoma patients receiving temozolomide (TMZ), respectively. In each figure, the days on which TMZ or IL-7 protein was administered are indicated. [Figure 20C] Figures A, B, and C show the effect of IL-7 protein administration on AUC, Ki67+CD8+ T cell frequency, and Ki67+CD4+ T cell frequency in glioblastoma patients receiving temozolomide (TMZ), respectively. In each figure, the days on which TMZ or IL-7 protein was administered are indicated. [Figure 21A]Figures A, B, and C show the effect of IL-7 protein administration on AUC, Ki67+CD8+ T cell frequency, and Ki67+CD4+ T cell frequency, respectively, in glioblastoma patients receiving Avastin / Irinotecan (A / I). In each figure, the days on which A / I or IL-7 protein was administered are indicated. [Figure 21B] Figures A, B, and C show the effect of IL-7 protein administration on AUC, Ki67+CD8+ T cell frequency, and Ki67+CD4+ T cell frequency, respectively, in glioblastoma patients receiving Avastin / Irinotecan (A / I). In each figure, the days on which A / I or IL-7 protein was administered are indicated. [Figure 21C] Figures A, B, and C show the effect of IL-7 protein administration on AUC, Ki67+CD8+ T cell frequency, and Ki67+CD4+ T cell frequency, respectively, in glioblastoma patients receiving Avastin / Irinotecan (A / I). In each figure, the days on which A / I or IL-7 protein was administered are indicated. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0042] I. Definition So that this disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise stated herein, each of the following terms shall have the meaning indicated below. Additional definitions are set forth throughout this specification.

[0043] Throughout this disclosure, the term "a" or "an" attached to an entity refers to one or more of that entity. For example, "an antibody" is understood to refer to one or more antibodies. Thus, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein.

[0044] Furthermore, "and / or" as used herein shall be construed as a specific disclosure of each of two particular features or components, with or without the other. Thus, the term "and / or" as used herein in phrases such as "A and / or B" is intended to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).

[0045] Whenever an embodiment is described herein with the word "comprising," it is to be understood that other similar embodiments described with the terms "consisting of" and / or "consisting essentially of" are also provided.

[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure pertains. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press, The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press, and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure.

[0047] Units, prefixes, and symbols are shown in their respective formats as accepted by the International System of Units (SI). Numerical ranges are inclusive of the numbers defining the range. Unless otherwise indicated, amino acid sequences are written from left to right in the amino to carboxy direction. The headings provided herein are not intended to limit the various aspects of the disclosure, which may be had by reference to the specification in its entirety. Thus, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0048] The term "about" is used herein to mean approximately, roughly, roughly, or within a range. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values ​​set forth. In general, the term "about" can modify a numerical value to be above or below the stated value, for example, by a variance of up to 10 percent (higher or lower).

[0049] As used herein, "administering" refers to the physical introduction of a therapeutic agent or a composition containing a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those skilled in the art. Various routes of administration of the therapeutic agents described herein include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal, or other parenteral routes of administration, for example, by injection or infusion. The phrase "parenteral administration" as used herein refers to modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, intratracheal, intrapulmonary, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraventricular, intravitreal, epidural, and intrasternal injection and infusion, and in vivo electroporation. Alternatively, the therapeutic agents described herein can be administered by a non-parenteral route, such as topical, epidermal, or mucosal routes of administration, e.g., intranasally, orally, vaginally, rectally, sublingually, or locally, and can be administered, e.g., once, multiple times, and / or over one or more extended periods of time.

[0050] As used herein, the term "antigen" means any natural or synthetic immunogenic substance, such as a protein, peptide, or hapten.

[0051] The terms "antibody" and "antibodies" are terms of art and may be used interchangeably herein to refer to a molecule that contains an antigen-binding site that specifically binds an antigen. As used herein, these terms include whole antibodies and any antigen-binding fragments (i.e., "antigen-binding portions") or single chains thereof. By "antibody" in one aspect is meant a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen-binding portion thereof. In another aspect, by "antibody" is meant a single chain antibody comprising a single variable domain, e.g., a VHH domain. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. In certain naturally occurring antibodies, the heavy chain constant region is composed of three domains, CH1, CH2 and CH3. In certain naturally occurring antibodies, each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is composed of one domain, CL.

[0052] The VH and VL regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), which are interspersed with more conserved regions called framework regions (FRs). Each VH and VL contains three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various immune system cells (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0053] Antibodies are typically -5 ~10 -11 The dissociation constant (K D ) specifically binds to its cognate antigen. D About 10 -4A binding affinity greater than 10 M is generally considered to indicate nonspecific binding. As used herein, an antibody that "specifically binds" to an antigen is one that binds to the antigen and to a substantially identical antigen with high affinity, i.e., greater than 10 M. -7 M or less, 10 -8 M or less, 5×10 -9 M or less, or 10 -8 M~10 -10 K below M D By "substantially identical" is meant an antibody that binds with high affinity to a given antigen but does not bind with high affinity to unrelated antigens. An antigen is "substantially identical" to a given antigen if it exhibits a high degree of sequence identity to the given antigen, e.g., at least 80%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity to the sequence of the given antigen. By way of example, an antibody that specifically binds to PD-1 may, in certain embodiments, have cross-reactivity with PD-1 antigens from a particular primate species (e.g., cynomolgus anti-PD-1 antibodies), but may not cross-react with PD-1 molecules from other species or with molecules other than PD-1.

[0054] Immunoglobulins may be derived from any of the commonly known isotypes, including, but not limited to, IgA, secretory IgA, IgG, and IgM. IgG subclasses are also well known to those of skill in the art and include, but are not limited to, human IgG1, IgG2, IgG3, and IgG4. By "isotype" is meant the class or subclass of antibody (e.g., IgM or IgG1) encoded by the heavy chain constant region genes. In certain embodiments, one or more amino acids of an isotype may be mutated to alter effector function. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies (Abs), monoclonal and polyclonal antibodies, chimeric and humanized antibodies, human or non-human antibodies, fully synthetic antibodies, and single chain antibodies. Non-human antibodies may be humanized by recombinant methods to reduce their immunogenicity in humans. Unless otherwise indicated, and unless the context dictates otherwise, the term "antibody" also includes antigen-binding fragments or portions of any of the aforementioned immunoglobulins, and also includes monovalent and divalent fragments or portions, as well as single-chain antibodies.

[0055] By "isolated antibody" is meant an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds PD-1 is substantially free of antibodies that specifically bind to antigens other than PD-1). However, an isolated antibody that specifically binds PD-1 may have cross-reactivity with other antigens, such as PD-1 molecules from different species. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0056] The term "monoclonal antibody" ("mAb") refers to a non-naturally occurring preparation of antibody molecules of single molecular composition, i.e., essentially identical in primary sequence and displaying a single binding specificity and affinity for a particular epitope. A mAb is an example of an isolated antibody. MAbs can be produced by hybridoma, recombinant, transgenic, or other techniques known to those of skill in the art.

[0057] A "human" antibody (HuMAb) refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region is also derived from a human germline immunoglobulin sequence. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced in vitro by random or site-specific mutagenesis, or mutations introduced in vivo by somatic mutation). However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The terms "human" antibody and "fully human" antibody are used interchangeably.

[0058] "Humanized antibody" refers to an antibody in which some, most, or all of the amino acids outside the CDR domain of a non-human antibody are replaced with the corresponding amino acids from a human immunoglobulin. In one embodiment of a humanized antibody, some, most, or all of the amino acids outside the CDR domain are replaced with amino acids from a human immunoglobulin, while some, most, or all of the amino acids in one or more CDR regions remain unchanged. Minor additions, deletions, insertions, substitutions, or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a specific antigen. A "humanized" antibody retains antigen specificity similar to that of the original antibody.

[0059] By "chimeric antibody" is meant an antibody whose variable region is derived from one species and whose constant region is derived from another species, such as an antibody whose variable region is derived from a mouse antibody and whose constant region is derived from a human antibody.

[0060] By "anti-antigen" antibody is meant an antibody that specifically binds to an antigen. For example, an anti-PD-1 antibody specifically binds to PD-1, and an anti-CTLA-4 antibody specifically binds to CTLA-4.

[0061] An "antigen-binding portion" of an antibody (also called an "antigen-binding fragment") means one or more fragments of an antibody that retain the ability to specifically bind to the antigen bound by the whole antibody.

[0062] As used herein, the terms "specific binding," "selective binding," "selectively binds," and "specifically binds" mean that an antibody binds to an epitope of a given antigen. Typically, an antibody (i) binds to an epitope of a given antigen, as determined by, for example, surface plasmon resonance (SPR) techniques on a BIACORE™ 2000 instrument using a given antigen as the analyte and an antibody as the ligand, or by Scatchard analysis of the binding of the antibody to antigen-positive cells, at a concentration of approximately 100 mM. -7 Less than M, e.g., about 10 -8 M, 10 -9 M or 10 -10 The equilibrium dissociation constant (K D ) and (ii) binds to a given antigen with an affinity that is at least two-fold higher than its binding affinity to a nonspecific antigen other than the given antigen or a closely related antigen (e.g., BSA, casein).

[0063] As used herein, the term "naturally occurring" when applied to an object refers to the fact that the object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses), that can be isolated from a natural source, and that has not been intentionally modified by humans in the laboratory, is naturally occurring.

[0064] A "polypeptide" refers to a chain comprising at least two consecutively linked amino acid residues, with no upper limit on the length of the chain. One or more amino acid residues in a protein may contain modifications, such as, but not limited to, glycosylation, phosphorylation, or disulfide bond formation. A "protein" may include one or more polypeptides. Unless otherwise specified, the terms "protein" and "polypeptide" may be used interchangeably.

[0065] The term "nucleic acid molecule" as used herein is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded and may be cDNA.

[0066] "Conservative amino acid substitution" means that an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), amino acids with non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), amino acids with β-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In certain embodiments, a predicted non-essential amino acid residue in an antibody is replaced with another amino acid residue from the same side chain family. Methods for identifying conservative nucleotide and amino acid substitutions that do not abolish antigen binding are well known in the art (see, e.g., Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999); and Burks et al. Proc. Natl. Acad. Sci. USA 94:412-417 (1997)).

[0067] With respect to nucleic acids, the term "substantial homology" indicates that two nucleic acids or their designated sequences, when optimally aligned and compared, are identical in at least about 80% of the nucleotides, at least about 90%-95%, or at least about 98%-99.5% of the nucleotides, with appropriate nucleotide insertions or deletions. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to the complement of the strand.

[0068] With respect to polypeptides, the term "substantial homology" indicates that two polypeptides or their designated sequences, when optimally aligned and compared, are identical in at least about 80% of the amino acids, at least about 90%-95%, or at least about 98%-99.5% of the amino acids, with appropriate amino acid insertions or deletions.

[0069] The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = number of identical positions / total number of positions x 100), taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap. The comparison of sequences and determination of the percent identity between two sequences can be performed, for example, using a mathematical algorithm, as described in the non-limiting examples below.

[0070] The percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at worldwideweb.gcg.com) using the NWSgapdna.CMP matrix and gap weights of 40, 50, 60, 70, or 80, and length weights of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989)) as incorporated into the ALIGN program (version 2.0) using a PAM120 residue weight table, a gap length penalty of 12, and a gap penalty of 4. Furthermore, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) incorporated into the GAP program of the GCG software package (available at worldwideweb.gcg.com), using either a Blossum 62 matrix or a PAM250 matrix, and gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6.

[0071] The nucleic acid and protein sequences described herein can also be used as "query sequences" to perform searches against public databases, for example to identify related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program using a score of 100 and word length of 12 to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed with the XBLAST program using a score of 50 and word length of 3 to obtain amino acid sequences homologous to the protein molecules described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (eg, XBLAST and NBLAST) can be used. See worldwideweb.ncbi.nlm.nih.gov.

[0072] Nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is "isolated" or "substantially pure" when it has been purified from other cellular components or other contaminants, such as other cellular nucleic acids (e.g., other parts of chromosomes) or proteins, by standard techniques, including alkaline / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and other techniques well known in the art. F. Ausubel, et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York, 1999. See York (1987).

[0073] Nucleic acids, e.g., cDNA, can be mutated according to standard techniques to produce gene sequences. For coding sequences, these mutations can affect the amino acid sequence as desired. In particular, DNA sequences substantially homologous to or derived from natural V, D, J, constant, switch, and other such sequences described herein are contemplated (where "derived" indicates that one sequence is identical to or modified from another sequence).

[0074] The term "vector" as used herein is intended to mean a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a "plasmid," which means a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, in which additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply "expression vectors"). In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids. As plasmids are the most commonly used form of vector, "plasmid" and "vector" may be used interchangeably herein. However, other forms of expression vectors, such as viral vectors (eg, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions are also included.

[0075] The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to mean a cell that contains a nucleic acid that does not naturally occur in the cell, and may be a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to mean not only the particular subject cell, but also the progeny of such a cell. Because certain modifications may occur in successive generations, either due to mutation or environmental influences, such progeny may not actually be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

[0076] As used herein, the term "linked" refers to the association of two or more molecules. The linkage may be covalent or non-covalent. The linkage may also be genetic (i.e., recombinant fusion). Such linkages may be accomplished using a wide range of art-recognized techniques, such as chemical conjugation and recombinant protein production.

[0077] "Cancer" refers to a broad group of diseases characterized by the uncontrolled growth of abnormal cells in the body. Uncontrolled cell division and growth leads to the formation of malignant tumors that may invade adjacent tissues and metastasize to distant parts of the body via the lymphatic system or bloodstream. As used herein, "cancer" refers to primary cancers, metastatic cancers, and recurrent cancers.

[0078] "Cytotoxic T-lymphocyte antigen-4" (CTLA-4) refers to an immunosuppressive receptor belonging to the CD28 family. CTLA-4 is expressed in vivo only on T cells and binds to two ligands, CD80 and CD86 (also called B7-1 and B7-2, respectively). As used herein, the term "CTLA-4" includes human CTLA-4 (hCTLA-4), variants, isoforms, and species homologs of hCTLA-4, as well as analogs that share at least one epitope in common with hCTLA-4. The complete hCTLA-4 sequence is available under Genbank accession number AAB59385.

[0079] The term "fusion protein" refers to a protein created by the joining of two or more genes that originally code for separate proteins. Translation of the fusion gene results in a single polypeptide or multiple polypeptides that have functional properties derived from each of the original proteins. In some embodiments, the two or more genes may contain substitutions, deletions, and / or additions in their nucleotide sequences.

[0080] An "Fc receptor" or "FcR" is a receptor that binds to the Fc region of an immunoglobulin. FcRs that bind IgG antibodies include receptors of the FcγR family, including allelic variants and alternatively spliced ​​forms of these receptors. The FcγR family consists of three activating receptors (FcγRI, FcγRIII, and FcγRIV in mice; FcγRIA, FcγRIIA, and FcγRIIIA in humans) and one inhibitory receptor (FcγRIIB). The various properties of human FcγRs are known in the art. While the majority of innate effector cell types co-express one or more activating FcγRs and inhibitory FcγRIIB, natural killer (NK) cells selectively express one activating Fc receptor (FcγRIII in mice and FcγRIIIA in humans) but not inhibitory FcγRIIB in mice and humans. Human IgG1 binds to most human Fc receptors and is considered equivalent to mouse IgG2a with respect to the types of activating Fc receptors it binds.

[0081] By "Fc region" (fragment crystallizable region) or "Fc domain" or "Fc" is meant the C-terminal region of an antibody heavy chain that mediates the binding of an immunoglobulin to host tissues or factors, including binding to Fc receptors located on various cells of the immune system (e.g., effector cells) or to the first component (C1q) of the classical complement system. Thus, the Fc region includes the constant region of an antibody except for the first constant region immunoglobulin domain (e.g., CH1 or CL). In IgG, IgA and IgD antibody isotypes, the Fc region includes two identical protein fragments derived from the second (CH2) and third (CH3) constant domains of the antibody's two heavy chains, while the Fc regions of IgM and IgE include three heavy chain constant domains (CH domains 2-4) in each polypeptide chain. In the case of IgG, the Fc region includes immunoglobulin domains CH2 and CH3, as well as the hinge between the CH1 and CH2 domains. As defined herein, the boundaries of the Fc region of an immunoglobulin heavy chain may vary, but the human IgG heavy chain Fc region is defined to extend from amino acid residues D221 for IgG1, V222 for IgG2, L221 for IgG3, and P224 for IgG4 to the carboxy-terminus of the heavy chain, where the numbering is according to the EU index as per Kabat. The CH2 domain of the human IgG Fc region extends from amino acid 237 to amino acid 340, and the CH3 domain is located C-terminal to the CH2 domain of the Fc region. That is, it extends from amino acid 341 to amino acid 447 or 446 (if the C-terminal lysine residue is absent) or 445 (if the C-terminal glycine and lysine residues are absent) of IgG. As used herein, an Fc region may be a native sequence Fc, including any allotypic variant, or variant Fc (e.g., a non-naturally occurring Fc). Fc may refer to this region alone or in the context of a protein polypeptide that contains Fc, such as an "Fc region-containing binding protein" (e.g., an antibody or immunoadhesin), also called an "Fc fusion protein."

[0082] A "native sequence Fc region" or "native sequence Fc" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. A native sequence human Fc region includes a native sequence human IgG1 Fc regions, native sequence human IgG2 Fc regions, native sequence human IgG3 Fc regions, and native sequence human IgG4 Fc regions, as well as naturally occurring variants thereof. Native sequence Fc includes the various allotypes of Fc (see, e.g., Jefferies, (see, e.g., et al. (2009) mAbs 1:1).

[0083] Furthermore, the Fc (native or variant) of the present invention may be in a form having native glycans, increased or decreased glycans compared to the native form, or may be deglycosylated. Immunoglobulin Fc glycans can be modified by conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms. Removal of glycans from the Fc fragment leads to a sharp decrease in binding affinity to the C1q portion of the first complement component C1, resulting in a decrease or loss of ADCC or CDC, and thus preventing the induction of unwanted immune responses in vivo. In this regard, deglycosylated or aglycosylated immunoglobulin Fc regions may be more suitable for the purpose of the present invention as drug carriers. As used herein, the term "deglycosylated" refers to an Fc region in which sugars have been enzymatically removed from the Fc fragment. Furthermore, the term "aglycosylated" refers to the Fc fragment being produced in a non-glycosylated form by a prokaryote, preferably in E. coli.

[0084] As used herein, the term "immune response" refers to a biological response in a vertebrate to foreign agents and protects the organism from these agents and the diseases they cause. An immune response is mediated by the action of immune system cells (e.g., T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells, or neutrophils) and soluble macromolecules (including antibodies, cytokines, and complement) produced by any of these cells or the liver, resulting in the selective targeting, binding, damage, destruction, and / or elimination of invading pathogens, pathogen-infected cells or tissues, cancer cells or other abnormal cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues in the vertebrate body. Immune responses include, for example, T cells, e.g., CD4 + Or CD8 + This includes the activation or inhibition of effector T cells, such as T cells, or Th cells, or the inhibition of Treg cells.

[0085] "Immunomodulator" or "immunoregulator" refers to an agent, e.g., a component of a signal transduction pathway, that may be involved in the regulation, control, or modification of an immune response. "Regulation," "control," or "modulation" of an immune response refers to any change in immune system cells or the activity of such cells (e.g., effector T cells). Such regulation includes stimulation or suppression of the immune system, which may be manifested by an increase or decrease in the number of various cell types, an increase or decrease in the activity of these cells, or any other change that may occur within the immune system. Both inhibitory and stimulatory immunomodulators have been identified, some of which may have improved function in the tumor microenvironment. In a preferred embodiment, the immunomodulator is located on the surface of a T cell. "Immunomodulatory target" or "immunoregulatory target" refers to an immunomodulator that is targeted for binding by a substance, agent, moiety, compound, or molecule, and whose activity is altered by this binding. Immunomodulatory targets include, for example, receptors ("immunomodulatory receptors") and receptor ligands ("immunomodulatory ligands") on the cell surface.

[0086] The term "immunotherapy" refers to treating a subject afflicted with a disease or at risk of developing or experiencing a recurrence of a disease by methods that involve inducing, enhancing, suppressing, or otherwise modifying the immune response. "Treatment" or "therapy" of a subject refers to any type of intervention or process, or administration of an active agent, performed on a subject for the purpose of reversing, alleviating, ameliorating, inhibiting, slowing, or preventing the onset, progression, manifestation, severity, or recurrence of symptoms, complications, or conditions, or biochemical signs associated with a disease.

[0087] By "immunostimulatory therapy" or "immunostimulatory therapy" is meant a therapy that results in augmentation (induction or enhancement) of the immune response, e.g., to treat cancer.

[0088] "Enhancing an endogenous immune response" means increasing the efficacy or potency of an existing immune response in a subject. Such an increase in efficacy and potency can be achieved, for example, by overcoming mechanisms that suppress the endogenous host immune response or by stimulating mechanisms that enhance the endogenous host immune response.

[0089] The term "effector T cells" (Teff) refers to T cells with cytolytic activity (e.g., CD4 + and CD8 + In addition to T cells, the immune system also includes helper T (Th) cells, which secrete cytokines and activate and induce other immune cells, but does not include regulatory T cells (Treg cells). The combination of IL-7 protein and immune checkpoint inhibitors (e.g., anti-PD-1 antibodies) increases the number of Teff cells, e.g., CD4 + and CD8 + Activates and / or increases the frequency of T cells.

[0090] As used herein, the term "regulatory T cells" (Tregs) refers to a T cell population that has the ability to regulate immune responses by reducing or suppressing the induction and proliferation of effector T cells. In some embodiments, Tregs can suppress immune responses by secreting anti-inflammatory cytokines such as IL-10, TGF-β, and IL-35, which can interfere with the activation and differentiation of naive T cells into effector T cells. In some embodiments, Tregs can also produce cytolytic molecules such as granzyme B, which can induce apoptosis of effector T cells. In some embodiments, regulatory T cells are endogenous regulatory T cells (nTregs) (i.e., develop in the thymus). In some embodiments, regulatory T cells are inducible regulatory T cells (iTregs) (i.e., naive T cells that differentiate into Tregs in peripheral tissues upon exposure to specific stimuli). Methods for identifying Tregs are known in the art. For example, Tregs express certain phenotypic markers (e.g., CD25, Foxp3, or CD39) that can be measured using flow cytometry. See, e.g., International Publication No. WO2017 / 062035A1, Gu J., et al., Cell Mol Immunol 14(6):521-528(2017). In some embodiments, Tregs express CD45RA - CD39 + T cells.

[0091] As used herein, the term "tumor-infiltrating lymphocytes" or "TILs" refers to lymphocytes (e.g., effector T cells) that have migrated from the periphery (e.g., from the blood) into a tumor. In some embodiments, the tumor-infiltrating lymphocytes are CD4+ TILs. In other embodiments, the tumor-infiltrating lymphocytes are CD8+ TILs.

[0092] The increased ability to stimulate an immune response or immune system may be due to improved agonist activity of T cell costimulatory receptors and / or improved antagonist activity of inhibitory receptors. The increased ability to stimulate an immune response or immune system may be reflected in the fold increase in EC50 or maximum activity level in assays that measure immune responses, such as assays that measure cytokine or chemokine release, cytolytic activity (directly determined on target cells or indirectly by detecting CD107a or granzymes), and changes in proliferation. The ability to stimulate an immune response or immune system activity may be increased by at least 10%, 30%, 50%, 75%, 2-fold, 3-fold, 5-fold, or more.

[0093] As used herein, the term "interleukin-7" or "IL-7" refers to IL-7 polypeptides and derivatives and analogs thereof that have substantial amino acid sequence identity and substantially equivalent biological activity to wild-type mature mammalian IL-7, e.g., in standard bioassays or assays of IL-7 receptor binding affinity. For example, IL-7 refers to the amino acid sequence of a recombinant or non-recombinant polypeptide having the amino acid sequence of i) a native IL-7 polypeptide, or a naturally occurring allelic variant of an IL-7 polypeptide, ii) a biologically active fragment of an IL-7 polypeptide, iii) a biologically active polypeptide analog of an IL-7 polypeptide, or iv) a biologically active variant of an IL-7 polypeptide. The IL-7 polypeptides of the present invention can be obtained from any species, e.g., human, bovine, or ovine. IL-7 nucleic acid and amino acid sequences are well known in the art. For example, the human IL-7 amino acid sequence is Genbank Accession No. P13232 (SEQ ID NO: 1), the mouse IL-7 amino acid sequence is Genbank Accession No. P10168 (SEQ ID NO: 3), the rat IL-7 amino acid sequence is Genbank Accession No. P56478 (SEQ ID NO: 2), the monkey IL-7 amino acid sequence is Genbank Accession No. NP_001279008 (SEQ ID NO: 4), the bovine IL-7 amino acid sequence is Genbank Accession No. P26895 (SEQ ID NO: 5), and the ovine IL-7 amino acid sequence is Genbank Accession No. Q28540 (SEQ ID NO: 6). In some embodiments, the IL-7 polypeptides of the disclosure are variants of the IL-7 protein.

[0094] A "variant" of an IL-7 protein is defined as an amino acid sequence in which one or more amino acids have been altered. A variant may have "conservative" changes, such as the substitution of a leucine with an isoleucine, in which the structural or chemical properties of the substituted amino acid are similar. Less commonly, a variant may have "non-conservative" changes, such as the substitution of a glycine with a tryptophan. Similar minor changes may include amino acid deletions or insertions, or both. Guidance in determining the type and number of amino acid residues that can be substituted, inserted, or deleted without losing biological activity can be found using computer programs well known in the art, such as software for molecular modeling or generating alignments. Variant IL-7 proteins included in the present invention include IL-7 proteins that retain IL-7 activity. Similarly, IL-7 polypeptides containing additions, substitutions, or deletions are included in the present invention, so long as the protein retains substantially equivalent biological IL-7 activity. For example, truncated forms of IL-7 that retain the same biological activity as the full-length IL-7 protein are included in the present invention. The activity of the IL-7 protein can be measured using an in vitro cell proliferation assay as described below in Example 6. The activity of the IL-7 variants of the invention maintains at least 10%, 20%, 40%, 60%, more preferably 80%, 90%, 95%, and even more preferably 99% of the biological activity compared to wild-type IL-7.

[0095] Variant IL-7 proteins also include polypeptides having at least about 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, 99% or more sequence identity with wild-type IL-7. To determine the percent identity of two amino acid sequences or two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps may be introduced into a first amino acid sequence or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = number of identical positions / total number of positions x 100). Determining the percent homology between two sequences can be performed using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for comparing two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-68, modified as described in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al., (1990) J. Mol. Biol. 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Research 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0096] As used herein, the term "Programmed Death-1 (PD-1)" refers to an immunosuppressive receptor belonging to the CD28 family. PD-1 is an in It is expressed primarily on previously activated T cells in vivo and binds to two ligands, PD-L1 and PD-L2. As used herein, the term "PD-1" includes human PD-1 (hPD-1), variants, isoforms, and species homologs of hPD-1, and analogs that share at least one epitope in common with hPD-1. The complete hPD-1 sequence is available under Genbank accession number U64863.

[0097] As used herein, the term "Programmed Death Ligand-1 (PD-L1)" refers to one of the two cell surface glycoprotein ligands of PD-1 (the other is PD-L2) that downregulates T cell activation and cytokine secretion upon binding to PD-1. As used herein, the term "PD-L1" includes human PD-L1 (hPD-L1), variants, isoforms, and species homologs of hPD-L1, and analogs that share at least one epitope in common with hPD-L1. The complete hPD-L1 sequence is available under Genbank accession number Q9NZQ7.

[0098] A "subject" includes any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the subject is a human. The terms "subject" and "patient" are used interchangeably herein.

[0099] The term "therapeutically effective amount" or "therapeutically effective dosage" refers to an amount of an agent that produces a desired biological, therapeutic, and / or prophylactic result. The result can be reduction, amelioration, alleviation, attenuation, delay, and / or relief of one or more of the signs, symptoms, or causes of a disease, or any other desired change in a biological system. With respect to solid tumors, an effective amount includes an amount sufficient to shrink the tumor and / or reduce the rate of growth of the tumor (e.g., inhibit tumor growth), or prevent or slow other undesirable cell proliferation. In some embodiments, an effective amount is an amount sufficient to slow the progression of the tumor. In some embodiments, an effective amount is an amount sufficient to prevent or slow the recurrence of the tumor. An effective amount can be administered in one or more administrations. An effective amount of a drug or composition can (i) reduce the number of cancer cells, (ii) reduce tumor size, (iii) inhibit, delay, slow to some extent, or stop the invasion of cancer cells into peripheral organs, (iv) inhibit (i.e., slow to some extent, or stop) tumor metastasis, (v) inhibit tumor growth, (vi) prevent or delay the onset and / or recurrence of tumors, and / or (vii) alleviate to some extent one or more symptoms associated with cancer. In some embodiments, a "therapeutically effective amount" is a combination of an amount of IL-7 protein and an amount of an immune checkpoint inhibitor (e.g., a PD-1 pathway inhibitor, e.g., an anti-PD-1 antibody) that has been clinically proven to result in a significant reduction in cancer, such as an advanced solid tumor, or a slowing (regression) of the progression of cancer. The ability of a therapeutic agent to promote disease regression can be assessed using a variety of methods known to the skilled practitioner, for example, by assaying the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.

[0100] The term "dosing frequency" refers to the number of times that a therapeutic agent (e.g., an IL-7 protein or an immune checkpoint inhibitor) is administered to a subject during a particular period of time. Dosing frequency can be indicated as the number of doses per given time, for example, once a day, once a week, or once every two weeks. As used herein, "dosing frequency" refers to when a subject receives multiple (or repeated) doses of a therapeutic agent.

[0101] As used herein, the term "standard of care" refers to treatment that is accepted by medical professionals as appropriate for a particular type of disease and is widely used by medical practitioners. This term may be used interchangeably with any of the following terms: "best practice," "standard of care," and "standard of care."

[0102] As used herein, the term "drug" refers to any bioactive agent (e.g., an IL-7 protein or an immune checkpoint inhibitor) intended for administration to a human or non-human mammal to prevent or treat a disease or other undesirable condition. Drugs include hormones, growth factors, proteins, peptides, and other compounds. In some embodiments, the drugs disclosed herein are anti-cancer drugs.

[0103] By way of example, an "anti-cancer drug" promotes the regression of a cancer in a subject or prevents further tumor growth. In certain embodiments, a therapeutically effective amount of a drug promotes the regression of a cancer to the point of eliminating the cancer. "Promoting the regression of a cancer" means that an effective amount of a drug administered alone or in combination with an anti-neoplastic agent results in a reduction in tumor growth or size, tumor necrosis, a decrease in the severity of at least one disease symptom, an increase in the frequency and duration of symptom-free periods of the disease, or prevention of functional or disabling disorders due to disease. Furthermore, the terms "effective" and "effectiveness" in relation to treatment include both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of a drug to promote the regression of a cancer in a patient. Physiological safety refers to the level of toxicity or other adverse physiological effects (adverse effects) at the cell, organ, and / or organism level resulting from administration of the drug.

[0104] As an example of tumor treatment, a therapeutically effective amount of an anti-cancer agent may inhibit cell or tumor growth by at least about 10%, at least about 20%, at least about 40%, at least about 60%, or at least about 80% compared to untreated subjects, or in certain embodiments, compared to patients treated with standard treatment regimens. In other embodiments of the invention, tumor regression may be observed and sustained for a period of at least about 20 days, at least about 40 days, or at least about 60 days. Regardless of these ultimate measures of therapeutic efficacy, evaluation of immunotherapeutics must also take into account "immune-related" response patterns.

[0105] As used herein, the term "immune checkpoint inhibitors" refers to molecules that fully or partially reduce, inhibit, interfere with, or modulate one or more checkpoint proteins. Checkpoint proteins control the activation or function of T cells. A number of checkpoint proteins are known, such as CTLA-4 and its ligands CD80 and CD86, and PD-1 and its ligands PD-L1 and PD-L2. Pardoll, DM, Nat Rev Cancer 12(4):252-64(2012). These proteins are responsible for costimulatory or inhibitory interactions in T cell responses. Immune checkpoint proteins control and maintain self-tolerance, as well as the duration and extent of physiological immune responses. Immune checkpoint inhibitors include or are derived from antibodies.

[0106] The term "reference" as used herein refers to a corresponding subject (e.g., a cancer subject) that did not receive the combination of IL-7 protein and an immune checkpoint inhibitor, e.g., a subject that received IL-7 protein alone or an immune checkpoint inhibitor alone. In some embodiments, the reference subject is one that did not receive either IL-7 protein or an immune checkpoint inhibitor. The term "reference" may also refer to the same cancer subject, but before administration of the combination of IL-7 protein and an immune checkpoint inhibitor. In certain embodiments, the term "reference" refers to the average of a population of subjects (e.g., cancer subjects).

[0107] As used herein, the terms "ug" and "uM" are used synonymously with "μg" and "μM", respectively.

[0108] The various aspects described herein are described in further detail in the following subsections.

[0109] II. Methods of the Disclosure The present disclosure relates to a method of treating a tumor (or cancer) in a subject in need thereof, comprising administering to the subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of an immune checkpoint inhibitor. Non-limiting examples of immune checkpoint inhibitors that can be used in the methods of the invention include anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, and combinations thereof.

[0110] In some embodiments, the combination of IL-7 protein and immune checkpoint inhibitors can increase the absolute lymphocyte count of a subject when administered to the subject. In certain embodiments, the absolute lymphocyte count is increased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% or more compared to a reference (e.g., the value of the corresponding subject after administration of IL-7 protein alone or immune checkpoint inhibitor alone).

[0111] In some embodiments, administration of a combination disclosed herein (i.e., a combination of an IL-7 protein and an immune checkpoint inhibitor) to a subject increases T cell proliferation (e.g., CD8 + T cells). In certain embodiments, the increase in T cell proliferation occurs in the periphery (e.g., outside of the tumor). In some embodiments, administration of a combination of IL-7 protein and an immune checkpoint inhibitor can result in the recruitment of effector T cells (e.g., cytotoxic CD8 + It can increase the recruitment of immune cells (cells that cause inflammation) and T lymphocytes.

[0112] In certain embodiments, T cell proliferation is increased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% or more compared to a reference (e.g., a value for a corresponding subject following administration of an IL-7 protein alone or an immune checkpoint inhibitor alone). In certain embodiments, T cells (e.g., CD8 + T cells) express one or more of the following markers: Eomesodermin (Eomes), Granzyme B, CXCR3, IFN-γ, or a combination thereof.

[0113] In certain embodiments, the recruitment of effector T cells to the tumor is increased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% or more as compared to a reference (e.g., values ​​for a corresponding subject following administration of an IL-7 protein alone or an immune checkpoint inhibitor alone).

[0114] In some embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor inhibits and / or reduces tumor growth in a subject, hi some embodiments, tumor growth (e.g., tumor volume or weight) is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., tumor volume in a corresponding subject after administration of an IL-7 protein alone or an immune checkpoint inhibitor alone).

[0115] In some embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor treats a tumor or a subject suffering from a tumor by promoting and / or enhancing an immune response to tumor antigens. In some embodiments, administration of a composition of the present disclosure increases the number of tumor infiltrating lymphocytes (TILs) (e.g., CD4 + or CD8 + In some embodiments, the number and / or percentage of TILs is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after administration compared to a reference (e.g., the number and / or percentage of TILs in a tumor in a subject treated with either an IL-7 protein alone or an immune checkpoint inhibitor alone).

[0116] In some embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor reduces the number and / or percentage of regulatory T cells (Tregs) in the subject's tumor. In some embodiments, regulatory T cells are CD4 + In some embodiments, the regulatory T cells are Foxp3 +In certain embodiments, the number and / or percentage of regulatory T cells in the tumor is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., the corresponding number and / or percentage in a subject receiving an IL-7 protein alone or an immune checkpoint inhibitor alone).

[0117] In some embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor increases CD8 expression in the subject's tumor. + The ratio of TILs to Tregs is increased. In certain embodiments, CD8 + The ratio of TILs to Tregs is increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after administration as compared to a reference (e.g., the number and / or percentage of TILs in a tumor of a subject treated with either the IL-7 protein alone or the immune checkpoint inhibitor alone).

[0118] In some embodiments, administration of a combination of IL-7 protein and immune checkpoint inhibitor reduces the number and / or percentage of myeloid-derived suppressor cells (MDSCs) in the subject's tumor. As used herein, the term "myeloid-derived suppressor cells" (MDSCs) refers to a heterogeneous population of immune cells defined by their myeloid origin, immature state, and ability to potently suppress T cell responses. They are known to proliferate in certain pathological conditions, such as chronic infections and cancer. In certain embodiments, the MDSCs are monocytic MDSCs (M-MDSCs). In other embodiments, the MDSCs are polymorphonuclear MDSCs (PMN-MDSCs). In some embodiments, the number and / or percentage of MDSCs in the tumor is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., a value in a corresponding subject after administration of an IL-7 protein alone or an immune checkpoint inhibitor alone).

[0119] In some embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor increases CD8 expression in the subject's tumor. + The ratio of TILs to MDSCs is increased. In a particular embodiment, CD8 + After administration, the ratio of TILs to MDSCs is increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% compared to a reference (e.g., the value of a corresponding subject after administration of IL-7 protein alone or an immune checkpoint inhibitor alone).

[0120] In some embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor reduces expression of an immune checkpoint inhibitor molecule (e.g., PD-1) in the subject's TILs. In certain embodiments, the combination of an IL-7 protein and an immune checkpoint inhibitor reduces the mean fluorescence index (MFI) of immune checkpoint inhibitor molecule (e.g., PD-1) expression in the TILs. In some embodiments, the immune checkpoint inhibitor molecule is PD-1. In certain embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor reduces CD8 + The MFI of PD-1 expression in TILs is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., corresponding number and / or percentage in subjects receiving IL-7 protein alone or an immune checkpoint inhibitor alone).

[0121] In some embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor increases the expression of a marker associated with effector (e.g., anti-tumor) activity in the TILs of the subject. Non-limiting examples of markers associated with effector activity include Ki-67, Granzyme B, T-bet, Eomes, CXCR3, IFN-γ, TNF-α, and IL-2. In certain embodiments, the markers associated with effector activity include Ki-67 and Granzyme B. In certain embodiments, the combination of an IL-7 protein and an immune checkpoint inhibitor increases the mean fluorescence index (MFI) of the expression of a marker associated with effector activity in the TILs by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100%, compared to a reference (e.g., a corresponding value in a subject that did not receive a combination of an IL-7 protein and an immune checkpoint inhibitor).

[0122] As mentioned above, many of the available standard cancer treatments (e.g., chemotherapy and radiation therapy) are known to cause lymphopenia, and many cancer patients are lymphopenic. Thus, the methods disclosed herein can also be used to treat cancer in lymphopenic subjects.

[0123] As used herein, the term "lymphopenic subject" refers to a subject having lymphopenia. As used herein, the terms "lymphopenia" and "lymphopenia" are used interchangeably and refer to a condition characterized by an abnormally low number of circulating immune cells (e.g., lymphocytes). In patients with lymphopenia, there is a high or low number of any type of lymphocyte or lymphocyte subpopulation (e.g., CD4 +The peripheral circulation of lymphocytes ("T lymphocytes") may be depleted or abnormally low. See, e.g., Lymphopenia Description, The Merck Manual (18th Edition, 2006, Merck & Co.). In some embodiments, compared to a normal subject (e.g., a healthy subject), a lymphopenic subject has a reduced number of T lymphocytes ("T lymphopenia"), B lymphocytes ("B lymphopenia"), and / or NK cells ("NK lymphopenia").

[0124] Lymphopenia can be quantitatively expressed by various cutoffs.In some embodiments, a lymphopenic subject has a circulating total lymphocyte count that is at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 100% less than the circulating total lymphocyte count of a corresponding subject that does not exhibit lymphopenia.In some embodiments, a subject has lymphopenia when the subject has a circulating total lymphocyte count that is less than about 1,500 lymphocytes per μL, less than about 1,000 lymphocytes per μL, less than about 800 lymphocytes per μL, less than about 500 lymphocytes per μL, or less than about 200 lymphocytes per μL.

[0125] There are a wide variety of possible causes of lymphopenia. In some embodiments, lymphopenia is caused by or associated with a tumor. In some embodiments, lymphopenia is associated with or caused by previous therapy (e.g., chemotherapy or radiation therapy) for a tumor. In some embodiments, lymphopenia is caused by or associated with infections, including viral infections (e.g., HIV infection or hepatitis infection), bacterial infections (e.g., active tuberculosis infection), and fungal infections, chronic right ventricular failure, Hodgkin's disease and cancers of the lymphatic system, leukemia, thoracic duct leakage or rupture, side effects of prescription drugs, including anti-cancer drugs, anti-viral drugs, and glucocorticoids, malnutrition caused by a low-protein diet, radiation therapy, uremia, autoimmune disorders, immune deficiency syndromes, high stress levels, and trauma.

[0126] In some embodiments, the lymphopenia is idiopathic (i.e., of unknown etiology). Non-limiting examples of idiopathic lymphopenia include idiopathic CD4 positive T lymphopenia (ICL), acute radiation syndrome (ARS), or a combination thereof.

[0127] In some embodiments, administration of an IL-7 protein in combination with an immune checkpoint inhibitor to a lymphopenic subject having a tumor inhibits and / or reduces tumor growth in the subject. In some embodiments, tumor growth (e.g., tumor volume or weight) is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., tumor volume in a corresponding subject after administration of the IL-7 protein alone or the immune checkpoint inhibitor alone).

[0128] In some embodiments, administration of an IL-7 protein in combination with an immune checkpoint inhibitor to a lymphopenic subject having a tumor reduces the number of tumor-infiltrating lymphocytes (TILs) (e.g., CD4 + or CD8 + In some embodiments, the number and / or percentage of TILs is increased by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after administration compared to a reference (e.g., the number and / or percentage of TILs in a tumor in a subject treated with either an IL-7 protein alone or an immune checkpoint inhibitor alone).

[0129] In some embodiments, administering an IL-7 protein in combination with an immune checkpoint inhibitor to a lymphopenic subject having a tumor reduces the number and / or percentage of regulatory T cells in the subject's tumor. + In certain embodiments, the number and / or percentage of regulatory T cells in the tumor is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., the corresponding number and / or percentage in a subject receiving an IL-7 protein alone or an immune checkpoint inhibitor alone).

[0130] In some embodiments, administering a combination of an IL-7 protein and an immune checkpoint inhibitor to a lymphopenic subject reduces CD8 in the subject's tumor. + The ratio of TILs to Tregs is increased. In certain embodiments, CD8 + The ratio of TILs to Tregs is increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after administration as compared to a reference (e.g., the number and / or percentage of TILs in a tumor of a subject treated with either the IL-7 protein alone or the immune checkpoint inhibitor alone).

[0131] In some embodiments, administering a combination of an IL-7 protein and an immune checkpoint inhibitor to a lymphopenic subject reduces expression of an immune checkpoint inhibitor molecule (e.g., PD-1) in the TILs of the subject. In certain embodiments, the combination of an IL-7 protein and an immune checkpoint inhibitor reduces the mean fluorescence index (MFI) of immune checkpoint inhibitor molecule (e.g., PD-1) expression in the TILs. In some embodiments, the immune checkpoint inhibitor molecule is PD-1. In certain embodiments, administration of a combination of an IL-7 protein and an immune checkpoint inhibitor reduces CD8 + The MFI of PD-1 expression in TILs is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., corresponding number and / or percentage in subjects receiving IL-7 protein alone or an immune checkpoint inhibitor alone).

[0132] Non-limiting examples of cancers (or tumors) that can be treated with the methods disclosed herein include squamous cell carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, gastrointestinal cancer, renal cancer (e.g., clear cell carcinoma), ovarian cancer, liver cancer (e.g., hepatocellular carcinoma), colon cancer, endometrial cancer, kidney cancer (e.g., renal cell carcinoma (RCC)), prostate cancer (e.g., hormone refractory prostate cancer), thyroid cancer, pancreatic cancer, cervical cancer, gastric cancer, bladder cancer, hepatoma, breast cancer, colon cancer, and head and neck cancer (or or carcinoma), gastric cancer, germ cell tumors, childhood sarcoma, sinonasal natural killer, melanoma (e.g. metastatic malignant melanoma, e.g. cutaneous or intraocular malignant melanoma), bone cancer, skin cancer, uterine cancer, cancer of the anal region, testicular cancer, fallopian tube cancer, endometrial carcinoma, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer (e.g. esophagogastric junction cancer), small intestine cancer, endocrine system cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, childhood solid tumors, ureteral cancer, renal pelvis cancer, tumor angiogenesis, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, ascites, Environmentally induced cancers, including those induced by vests, virus-associated cancers or cancers of viral origin (e.g., tumors associated with or derived from human papillomavirus (HPV)), and hematological malignancies derived from either of the two major blood cell lineages, i.e., myeloid lineage (producing granulocytes, erythrocytes, platelets, macrophages, and mast cells) or lymphoid lineage (producing B cells, T cells, NK cells, and plasma cells), e.g., all types of leukemias, lymphomas, and myelomas, e.g., acute, chronic, lymphocytic, and / or myelomas, including leukemias, lymphomas, and ... myeloid leukemias, such as acute myeloid leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), anaplastic AML (MO), myeloblastic leukemia (Ml), myeloblastic leukemia (M2; with cellular maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or M4 variant with eosinophilia [M4E]), monocytic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), isolated granulocytic sarcoma, and chloroma;Lymphomas, e.g., Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), B-cell hematological malignancies, e.g., B-cell lymphoma, T-cell lymphoma, lymphoplasmacytic lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., Ki1; + )Large cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, hemangiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphoblastic lymphoma, T-lymphoblastic; and lymphoma / leukemia (T-Lbly / T-ALL), peripheral T-cell lymphoma, lymphoblastic lymphoma, post-transplant lymphoproliferative disorder, true histiocytic lymphoma, primary somatic Liquid lymphoma, B-cell lymphoma, lymphoblastic lymphoma (LBL), hematopoietic neoplasms of the lymphatic system, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also called mycosis fungoides or Sézary syndrome), and Waldenström-Stöckel syndrome. Lymphoplasmacytic lymphoma (LPL) with hematopoietic macroglobulinemia; myelomas, e.g., IgG myeloma, light chain myeloma, nonsecretory myeloma, smoldering myeloma (also called asymptomatic myeloma), solitary plasmacytoma, and multiple myeloma, chronic lymphocytic leukemia (CLL), hairy cell lymphoma; hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; seminoma, teratoma, fibrosarcoma, rhabdomyosarcoma, and rhabdomyosarcoma; tumors of mesenchymal origin, including rhabdomyosarcoma, and osteosarcoma; as well as other tumors, such as melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, follicular thyroid carcinoma and teratoma, hematopoietic tumors of the lymphatic system, such as T-cell tumors and B-cell tumors, including, but not limited to, T-prolymphocytic leukemia (T-PLL) including small cell and cerebriform cell types, T-cell types of large granular lymphocyte leukemia (LGL); a / d T-NHL hepatosplenic lymphoma; peripheral / post-thymic T-cell lymphoma (pleomorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; head and neck cancer, renal cancer, rectal cancer, thyroid cancer; acute myeloid lymphoma, and any combination thereof.

[0133] In some embodiments, the cancer (or tumor) that can be treated includes breast cancer, head and neck cancer, uterine cancer, brain cancer, skin cancer, kidney cancer, lung cancer, colon cancer, prostate cancer, liver cancer, bladder cancer, kidney cancer, pancreatic cancer, thyroid cancer, esophageal cancer, eye cancer, stomach cancer (gastric cancer), gastrointestinal cancer, carcinoma, sarcoma, leukemia, lymphoma, myeloma, or a combination thereof. In certain embodiments, the cancer (or tumor) that can be treated with the method of the present invention is breast cancer. In some embodiments, the breast cancer is triple negative breast cancer (TNBC). In some embodiments, the cancer (or tumor) that can be treated is brain cancer. In certain embodiments, the brain cancer is glioblastoma. In some embodiments, the cancer (or tumor) that can be treated with the method of the present invention is skin cancer. In some embodiments, the skin cancer is basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), melanoma, Merkel cell carcinoma (MCC), or a combination thereof. In certain embodiments, the head and neck cancer is head and neck squamous cell carcinoma. In further embodiments, the lung cancer is small cell lung cancer (SCLC). In some embodiments, the esophageal cancer is esophagogastric junction cancer. In certain embodiments, the kidney cancer is renal cell carcinoma. In some embodiments, the liver cancer is hepatocellular carcinoma.

[0134] In some embodiments, the methods described herein may also be used to treat metastatic cancer, unresectable refractory cancer (e.g., cancer that has been refractory to previous cancer therapy, e.g., immunotherapy, e.g., therapy with an anti-PD-1 blocking antibody), and / or recurrent cancer. In certain embodiments, the previous cancer therapy comprises chemotherapy. In some embodiments, the chemotherapy comprises a platinum-based therapy. In some embodiments, the platinum-based therapy comprises a platinum-based anti-neoplastic agent selected from the group consisting of cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, and any combination thereof. In certain embodiments, the platinum-based therapy comprises cisplatin. In further embodiments, the platinum-based therapy comprises carboplatin.

[0135] In some embodiments, the subject treated with the methods disclosed herein has undergone one, two, three, four, five, or more previous cancer treatments. In other embodiments, the subject is treatment naive (i.e., has never previously undergone a cancer treatment). In some embodiments, the subject has progressed to other cancer treatments. In certain embodiments, the previous cancer treatment included immunotherapy (e.g., with an anti-PD-1 antibody). In other embodiments, the previous cancer treatment included chemotherapy. In some embodiments, the tumor has recurred. In some embodiments, the tumor is metastatic. In other embodiments, the tumor is not metastatic.

[0136] In some embodiments, the methods disclosed herein effectively prolong the survival of a subject in need thereof (e.g., suffering from a tumor). For example, in some embodiments, the survival of the subject is prolonged by at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, or at least about 1 year or more, when compared to a reference individual (e.g., a corresponding subject treated with IL-7 protein alone or an immune checkpoint inhibitor alone). In other embodiments, the methods disclosed herein prolong the survival of the subject at a level higher (about 1 month higher, about 2 months higher, about 3 months higher, about 4 months higher, about 5 months higher, about 6 months higher, about 7 months higher, about 8 months higher, about 9 months higher, about 10 months higher, about 11 months higher, or about 1 year higher) than the survival of a reference subject (e.g., a corresponding subject treated with IL-7 protein alone or an immune checkpoint inhibitor alone).

[0137] In some embodiments, the method of the present disclosure effectively extends the progression-free survival of a subject (e.g., a cancer patient).For example, the progression-free survival of a subject is extended by at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, or at least about 1 year, when compared with a reference subject (e.g., a corresponding subject treated with IL-7 protein alone or an immune checkpoint inhibitor alone).

[0138] In some embodiments, the methods disclosed herein effectively increase the response rate of a subject group. For example, the response rate of a subject group is increased by at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or at least about 100% when compared with a reference subject (e.g., a corresponding subject treated with IL-7 protein alone or an immune checkpoint inhibitor alone).

[0139] In some embodiments, the subject treated with the methods is a non-human animal, such as a rat or a mouse. In some embodiments, the subject treated with the methods is a human.

[0140] In some embodiments, the unit dose of the IL-7 protein disclosed herein (e.g., for human use) may be in the range of 0.001 mg / kg to 10 mg / kg. In certain embodiments, the unit dose of the IL-7 protein is in the range of 0.01 mg / kg to 2 mg / kg. In some embodiments, the unit dose is in the range of 0.02 mg / kg to 1 mg / kg. The unit dose may vary depending on the disease being treated and the presence of adverse effects. Administration of the IL-7 protein may be by periodic bolus injections or from an external reservoir (e.g., an IV bag), or by continuous intravenous, subcutaneous, or intraperitoneal administration from an internal (e.g., bioerodible implant). In certain embodiments, the IL-7 protein disclosed herein is administered by intramuscular injection.

[0141] In some embodiments, the IL-7 protein disclosed herein may be administered to a subject at a weight-based dose. In certain embodiments, the IL-7 protein may be administered at a weight-based dose of about 20 μg / kg to about 600 μg / kg. In further embodiments, the IL-7 protein disclosed herein may be administered at a weight-based dose of about 20 μg / kg, about 60 μg / kg, about 120 μg / kg, about 240 μg / kg, about 360 μg / kg, about 480 μg / kg, or about 600 μg / kg.

[0142] In some embodiments, the IL-7 protein disclosed herein may be administered to a subject at a dose of more than about 600 μg / kg. In certain embodiments, the IL-7 protein is administered to a subject at a dose of more than about 600 μg / kg, more than about 700 μg / kg, more than about 800 μg / kg, more than about 900 μg / kg, more than about 1,000 μg / kg, more than about 1,100 μg / kg, more than about 1,200 μg / kg, more than about 1,300 μg / kg, more than about 1,400 μg / kg, more than about 1,500 μg / kg, more than about 1,600 μg / kg, more than about 1,700 μg / kg, more than about 1,800 μg / kg, more than about 1,900 μg / kg, or more than about 2,000 μg / kg.

[0143] In some embodiments, the IL-7 protein of the present disclosure is administered in a dose range of 610 μg / kg to about 1,200 μg / kg, 650 μg / kg to about 1,200 μg / kg, about 700 μg / kg to about 1,200 μg / kg, about 750 μg / kg to about 1,200 μg / kg, about 800 μg / kg to about 1,200 μg / kg, about 850 μg / kg to about 1,200 μg / kg, about 900 μg / kg to about 1,200 μg / kg, about 950 μg / kg to about 1,200 μg / kg, about 1,000 μg / kg to about 1,200 μg / kg, about 1,050 μg / kg to about 1,200 μg / kg, about 1,100 μg / kg to about 1,200 μg / kg, or about 1,200 μg / kg. 0 μg / kg ~ approx. 2,000 μg / kg, approx. 1,300 μg / kg ~ approx. 2,000 μg / kg, approx. 1,500 μg / kg ~ approx. 2,000 μg / kg, approx. 1 , 700 μg / kg ~ approx. 2,000 μg / kg, approx. 610 μg / kg ~ approx. 1,000 μg / kg, approx. 650 μg / kg ~ approx. 1,000 μg / kg, approx. 700 The therapeutic agent is administered at a dose of about 750 μg / kg to about 1,000 μg / kg, about 800 μg / kg to about 1,000 μg / kg, about 850 μg / kg to about 1,000 μg / kg, about 900 μg / kg to about 1,000 μg / kg, or about 950 μg / kg to about 1,000 μg / kg.

[0144] In some embodiments, the IL-7 protein of the present disclosure is administered at a dose of 610 μg / kg to about 1,200 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of 650 μg / kg to about 1,200 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg to about 1,200 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 750 μg / kg to about 1,200 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 800 μg / kg to about 1,200 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 850 μg / kg to about 1,200 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 900 μg / kg to about 1,200 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 950 μg / kg to about 1,200 μg / kg. In some embodiments, the IL-7 protein disclosed herein is administered at a dose of about 1,000 μg / kg to about 1,200 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,050 μg / kg to about 1,200 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,100 μg / kg to about 1,200 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,200 μg / kg to about 2,000 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,300 μg / kg to about 2,000 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,500 μg / kg to about 2,000 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,700 μg / kg to about 2,000 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 610 μg / kg to about 1,000 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 650 μg / kg to about 1,000 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg to about 1,000 μg / kg.In still further embodiments, the IL-7 protein is administered at a dose of about 750 μg / kg to about 1,000 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 800 μg / kg to about 1,000 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 850 μg / kg to about 1,000 μg / kg. In some embodiments, the IL-7 protein of the present disclosure is administered at a dose of about 900 μg / kg to about 1,000 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 950 μg / kg to about 1,000 μg / kg.

[0145] In some embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg to about 900 μg / kg, about 750 μg / kg to about 950 μg / kg, about 700 μg / kg to about 850 μg / kg, about 750 μg / kg to about 850 μg / kg, about 700 μg / kg to about 800 μg / kg, about 800 μg / kg to about 900 μg / kg, about 750 μg / kg to about 850 μg / kg, or about 850 μg / kg to about 950 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg to about 900 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 750 μg / kg to about 950 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg to about 850 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 750 μg / kg to about 850 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg to about 800 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 800 μg / kg to about 900 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 750 μg / kg to about 850 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 850 μg / kg to about 950 μg / kg.

[0146] In some embodiments, the IL-7 protein is about 650 μg / kg, about 680 μg / kg, about 700 μg / kg, about 720 μg / kg, about 740 μg / kg, about 750 μg / kg, about 760 μg / kg, about 780 μg / kg, about 800 μg / kg, about 820 μg / kg, about 840 μg / kg, about 850 μg / kg, about 860 μg / kg, about 880 μg / kg, about 900 μg / kg, about 920 μg / kg, about 940 μg / kg, about 950 μg / kg, about 960 μg / kg g, approximately 980μg / kg, approximately 1,000μg / kg, approximately 1,020μg / kg, approximately 1,040μg / kg, approximately 1,060μg / kg, approximately 1,080μg / kg, approximately 1,100μg / kg, approximately 1,120μg / kg, approximately 1,140μg / k g, approximately 1,160μg / kg, approximately 1,180μg / kg, approximately 1,200μg / kg, approximately 1,220μg / kg, approximately 1,240μg / kg, approximately 1,260μg / kg, approximately 1,280μg / kg, approximately 1,300μg / kg, approximately 1,320μg / kg, approximately 1,340μg / kg, approximately 1,360μg / kg, approximately 1,380μg / kg, approximately 1,400μg / kg, approximately 1,420μg / kg, approximately 1,440μg / kg, approximately 1,460μg / kg, approximately 1,480μg / kg, approximately 1,500 1,6 The IL-7 protein is administered at a dose of about 80 μg / kg, about 1,700 μg / kg, about 1,720 μg / kg, about 1,740 μg / kg, about 1,760 μg / kg, about 1,780 μg / kg, about 1,800 μg / kg, about 1,820 μg / kg, about 1,840 μg / kg, about 1,860 μg / kg, about 1,880 μg / kg, about 1,900 μg / kg, about 1,920 μg / kg, about 1,940 μg / kg, about 1,960 μg / kg, about 1,980 μg / kg, or about 2,000 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 650 μg / kg. In other embodiments, the IL-7 protein disclosed herein is administered at a dose of about 680 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 700 μg / kg.In some embodiments, the IL-7 protein is administered at a dose of about 720 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 740 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 750 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 760 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 780 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 800 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 820 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 840 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 850 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 860 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 880 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 900 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 920 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 940 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 950 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 960 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 980 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,000 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,020 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,040 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,060 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,080 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,100 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,120 μg / kg.In further embodiments, the IL-7 protein is administered at a dose of about 1,140 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,160 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,180 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,200 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,220 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,240 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,260 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,280 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,300 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,320 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,340 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,360 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,380 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,400 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,420 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,440 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,460 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,480 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,500 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,520 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,540 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,560 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,580 μg / kg.In some embodiments, the IL-7 protein is administered at a dose of about 1,600 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,620 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,640 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,660 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,680 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,700 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,720 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,740 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,760 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,780 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,800 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,820 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,840 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,860 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,880 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,900 μg / kg. In certain embodiments, the IL-7 protein is administered at a dose of about 1,920 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 1,940 μg / kg. In some embodiments, the IL-7 protein is administered at a dose of about 1,960 μg / kg. In other embodiments, the IL-7 protein is administered at a dose of about 1,980 μg / kg. In further embodiments, the IL-7 protein is administered at a dose of about 2,000 μg / kg.

[0147] In some embodiments, the IL-7 protein may be administered at a fixed dose. In certain embodiments, the IL-7 protein may be administered at a fixed dose of about 0.25 mg to about 9 mg. In some embodiments, the IL-7 protein may be administered at a fixed dose of about 0.25 mg, about 1 mg, about 3 mg, about 6 mg, or about 9 mg.

[0148] In some embodiments, the IL-7 protein disclosed herein is administered to a subject in multiple doses (i.e., repeated administration). In certain embodiments, the IL-7 protein is administered to a subject at least two times, at least three times, at least four times, at least five times, at least six times, at least seven times, at least eight times, at least nine times, or at least ten times or more. In other embodiments, the subject receives a single administration of the IL-7 protein (e.g., before, simultaneously with, or after administration of an immune checkpoint inhibitor).

[0149] In some embodiments, the IL-7 protein is administered at a dosing frequency of about once per week, about once per 2 weeks, about once per 3 weeks, about once per 4 weeks, about once per 5 weeks, about once per 6 weeks, about once per 7 weeks, about once per 8 weeks, about once per 9 weeks, about once per 10 weeks, about once per 11 weeks, or about once per 12 weeks. In certain embodiments, the IL-7 protein is administered at a dosing frequency of about once per 10 days, about once per 20 days, about once per 30 days, about once per 40 days, about once per 50 days, about once per 60 days, about once per 70 days, about once per 80 days, about once per 90 days, or about once per 100 days. In some embodiments, the IL-7 protein is administered once per 3 weeks. In some embodiments, the IL-7 protein is administered once per week. In some embodiments, the IL-7 protein is administered once every 2 weeks. In some embodiments, the IL-7 protein is administered once every 4 weeks. In certain embodiments, the IL-7 protein is administered once every 6 weeks. In further embodiments, the IL-7 protein is administered once every 8 weeks. In some embodiments, the IL-7 protein is administered once every 9 weeks. In certain embodiments, the IL-7 protein is administered once every 12 weeks. In some embodiments, the IL-7 protein is administered once every 10 days. In certain embodiments, the IL-7 protein is administered once every 20 days. In other embodiments, the IL-7 protein is administered once every 30 days. In some embodiments, the IL-7 protein is administered once every 40 days. In certain embodiments, the IL-7 protein is administered once every 50 days. In some embodiments, the IL-7 protein is administered once every 60 days. In further embodiments, the IL-7 protein is administered once every 70 days. In some embodiments, the IL-7 protein is administered once every 80 days. In certain embodiments, the IL-7 protein is administered once every 90 days. In some embodiments, the IL-7 protein is administered once every 100 days.

[0150] In some embodiments, the IL-7 protein is administered in an amount of about 720 μg / kg, two or more times at intervals of about 1 week, about 2 weeks, about 3 weeks, or about 4 weeks. In some embodiments, the IL-7 protein is administered in an amount of about 840 μg / kg, two or more times at intervals of about 2 weeks, about 3 weeks, about 4 weeks, or about 5 weeks. In some embodiments, the IL-7 protein is administered in an amount of about 960 μg / kg, two or more times at intervals of about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, or about 6 weeks. In some embodiments, the IL-7 protein is administered in an amount of about 1200 μg / kg, two or more times at intervals of about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, or about 8 weeks. In some embodiments, the IL-7 protein is administered in an amount of about 1440 μg / kg two or more times at intervals of about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 8 weeks, about 10 weeks, about 12 weeks, or about 3 months.

[0151] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once per week. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once per week. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once per week. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once per week. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once per week. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once per week. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once per week.

[0152] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every two weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every two weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every two weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every two weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every two weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every two weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a biweekly dosing frequency. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a biweekly dosing frequency. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a biweekly dosing frequency.

[0153] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every three weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every three weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every three weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every three weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every three weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every three weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every three weeks.

[0154] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every four weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every four weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every four weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every four weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every four weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every four weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every four weeks.

[0155] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 5 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 5 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 5 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 5 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 5 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 5 weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 5 weeks.

[0156] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 6 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 6 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 6 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 6 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 6 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 6 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every six weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every six weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every six weeks.

[0157] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 7 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 7 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 7 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 7 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 7 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 7 weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 7 weeks.

[0158] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 8 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 8 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 8 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 8 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 8 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 8 weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 8 weeks.

[0159] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 9 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 9 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 9 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 9 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 9 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 9 weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 9 weeks.

[0160] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 10 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 10 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 10 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 10 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 10 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 10 weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 10 weeks.

[0161] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 11 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 11 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 11 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 11 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 11 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 11 weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 11 weeks.

[0162] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 12 weeks. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 12 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 12 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 12 weeks. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 12 weeks. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 12 weeks. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 12 weeks.

[0163] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 10 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 10 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 10 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 10 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 10 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 10 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 10 days.

[0164] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 20 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 20 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 20 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 20 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 20 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 20 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 20 days.

[0165] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 30 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 30 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 30 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 30 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 30 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 30 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 30 days.

[0166] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 40 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 40 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 40 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 40 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 40 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 40 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 40 days.

[0167] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 50 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 50 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 50 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 50 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 50 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 50 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 50 days.

[0168] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 60 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 60 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 60 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 60 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 60 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 60 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 60 days.

[0169] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 70 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 70 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 70 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 70 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 70 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 70 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 70 days.

[0170] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 80 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 80 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 80 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 80 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 80 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 80 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 80 days.

[0171] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 90 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 90 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 90 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 90 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 90 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 90 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 90 days.

[0172] In some embodiments, the IL-7 protein is administered at a dose of 60 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 120 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 240 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 480 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 720 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 960 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 1,200 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 1,300 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 1,400 μg / kg with a dosing frequency of once every 100 days. In other embodiments, the IL-7 protein is administered at a dose of 1,420 μg / kg with a dosing frequency of once every 100 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,440 μg / kg with a dosing frequency of once every 100 days. In further embodiments, the IL-7 protein is administered at a dose of 1,460 μg / kg with a dosing frequency of once every 100 days. In certain embodiments, the IL-7 protein is administered at a dose of 1,480 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 1,500 μg / kg with a dosing frequency of once every 100 days. In further embodiments, the IL-7 protein is administered at a dose of 1,600 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 1,700 μg / kg with a dosing frequency of once every 100 days. In some embodiments, the IL-7 protein is administered at a dose of 2,000 μg / kg with a dosing frequency of once every 100 days.

[0173] In some embodiments, the methods disclosed herein (e.g., administering an IL-7 protein in combination with an immune checkpoint inhibitor) can be used in combination with one or more additional anti-cancer and / or immunomodulatory agents. Such agents can include, for example, chemotherapeutic agents, small molecule drugs, or antibodies that stimulate an immune response to a given cancer. In some embodiments, the methods described herein are used in combination with standard of care treatments (e.g., surgery, radiation, and chemotherapy). The methods described herein can also be used as maintenance therapy, e.g., therapy aimed at preventing tumor development or recurrence.

[0174] In some embodiments, the methods of treating tumors disclosed herein may include administering IL-7 protein in combination with one or more immuno-oncology agents, such that multiple components of the immune pathway can be targeted. Non-limiting examples of such combinations include therapies that enhance tumor antigen presentation (e.g., dendritic cell vaccines, GM-CSF-secreting cell vaccines, CpG oligonucleotides, imiquimod); therapies that inhibit negative immune regulation, for example, by inhibiting the CTLA-4 and / or PD1 / PD-L1 / PD-L2 pathways and / or depleting or blocking Tregs or other immune suppressive cells (e.g., myeloid-derived suppressor cells); therapies that stimulate positive immune regulation, for example, by agonists that stimulate the CD-137, OX-40, and / or CD40 or GITR pathways and / or stimulate T cell effector function; therapies that systemically increase the frequency of anti-tumor T cells; for example, by using antagonists of CD25 (e.g., daclizumab) or ex vivo. These include therapies that deplete or inhibit Tregs, such as Tregs in tumors by in vivo anti-CD25 bead depletion; therapies that affect the function of suppressor myeloid cells in tumors; therapies that improve the immunogenicity of tumor cells (e.g., anthracyclines); adoptive transfer of T cells or NK cells, including genetically modified cells, e.g., cells modified with chimeric antigen receptors (CAR-T therapy); therapies that inhibit metabolic enzymes such as indoleamine dioxygenase (IDO), dioxygenase, arginase, or nitric oxide synthase; therapies that reverse / prevent T cell anergy or exhaustion; therapies that induce innate immune activation and / or inflammation at the tumor site; administration of immune stimulatory cytokines; or blockade of immune suppressive cytokines.

[0175] In some embodiments, immuno-oncology agents that can be used in combination with the IL-7 proteins disclosed herein include immune checkpoint inhibitors (i.e., block signaling by a particular immune checkpoint pathway). Non-limiting examples of immune checkpoint inhibitors that can be used in the methods of the present invention include CTLA-4 antagonists (e.g., anti-CTLA-4 antibodies), PD-1 antagonists (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies), TIM-3 antagonists (e.g., anti-TIM-3 antibodies), or combinations thereof.

[0176] In some embodiments, the immuno-oncology agent comprises an immune checkpoint activator (i.e., promotes signaling by a particular immune checkpoint pathway). In certain embodiments, the immune checkpoint activator comprises an OX40 agonist (e.g., an anti-OX40 antibody), a LAG-3 agonist (e.g., an anti-LAG-3 antibody), a 4-1BB (CD137) agonist (e.g., an anti-CD137 antibody), a GITR agonist (e.g., an anti-GITR antibody), or any combination thereof.

[0177] In some embodiments, the combination of the IL-7 protein described herein and the second agent (e.g., immune checkpoint inhibitor) may be administered simultaneously as a single composition in a pharma- ceutically acceptable carrier. In other embodiments, the combination of the IL-7 protein described herein and the second agent (e.g., immune checkpoint inhibitor) may be administered simultaneously as separate compositions. In further embodiments, the combination of the IL-7 protein described herein and the second agent (e.g., immune checkpoint inhibitor) may be administered sequentially. In some embodiments, the IL-7 protein is administered prior to administration of the second agent (e.g., immune checkpoint inhibitor).

[0178] IIa. IL-7 Proteins Useful in the Disclosure Disclosed herein are IL-7 proteins that can be used in combination with immune checkpoint inhibitors to treat cancer (or tumors). In some embodiments, the IL-7 protein useful for this use can be wild-type IL-7 or modified IL-7 (i.e., an IL-7 protein that is not wild-type) (e.g., an IL-7 variant, an IL-7 functional fragment, an IL-7 derivative, or any combination thereof, e.g., a fusion protein, a chimeric protein, etc.), provided that the IL-7 protein comprises one or more biological activities of IL-7, e.g., can bind to IL-7R, e.g., induce early T cell development, promote T cell homeostasis. ElKassar and See Gress. J Immunotoxicol. 2010 Mar;7(1):1-7. In some embodiments, the IL-7 proteins of the present disclosure are not wild-type IL-7 proteins (i.e., contain one or more modifications). Non-limiting examples of such modifications may include oligopeptides and / or half-life extending moieties. See WO2016 / 200219, which is incorporated herein by reference in its entirety.

[0179] IL-7 binds to a receptor composed of two chains, IL-7Rα (CD127) shared with thymic stromal lymphopoietin (TSLP) (Ziegler and Liu, 2006) and γ chain (CD132) shared with IL-2, IL-15, IL-9, and IL-21. IL-7Rα is expressed almost exclusively on lymphoid cells, whereas γc is expressed on most hematopoietic cells. After binding to its receptor, IL-7 signals through two distinct pathways, Jak-Stat (Janus kinase-Signal transducer and activator of transcription) and PI3K / Akt, which are involved in differentiation and survival, respectively. Lack of IL-7 signaling is responsible for the reduced thymic cellularity observed in mice given anti-IL-7 neutralizing monoclonal antibodies (MAbs) (Grabstein et al., 1993), IL-7- / - mice (von Freeden-Jeffry et al., 1995), IL-7Rα- / - mice (Peschon et al., 1994; Maki et al., 1996), γc- / - mice (Malissen et al., 1997), and Jak3- / - mice (Park et al., 1995). Mice lacking IL-7 signaling have a deficiency in T cells, B cells, and NK-T cells. IL-7α- / - mice (Peschon et al., 1994) have a similar but more severe phenotype as IL-7- / - mice (von Freeden-Jeffry et al., 1995), possibly because TSLP signaling is also suppressed in IL-7α- / - mice. IL-7 is required for the development of γδ cells (Maki et al., 1996) and NK-T cells (Boesteanu et al., 1997).

[0180] In some embodiments, an IL-7 protein useful in the present disclosure comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1-6. In other embodiments, an IL-7 protein comprises an amino acid sequence having about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% or more sequence identity to a sequence of SEQ ID NOs: 1-6.

[0181] In some embodiments, the IL-7 protein comprises a modified IL-7 or a fragment thereof, which retains one or more biological activities of wild-type IL-7. In some embodiments, the IL-7 protein may be derived from a human, rat, mouse, monkey, cow, or sheep.

[0182] In some embodiments, human IL-7 may have the amino acid sequence represented in SEQ ID NO:1 (Genbank Accession No. P13232), rat IL-7 may have the amino acid sequence represented in SEQ ID NO:2 (Genbank Accession No. P56478), mouse IL-7 may have the amino acid sequence represented in SEQ ID NO:3 (Genbank Accession No. P10168), monkey IL-7 may have the amino acid sequence represented in SEQ ID NO:4 (Genbank Accession No. NP 001279008), bovine IL-7 may have the amino acid sequence represented in SEQ ID NO:5 (Genbank Accession No. P26895), and ovine IL-7 may have the amino acid sequence represented in SEQ ID NO:6 (Genbank Accession No. Q28540).

[0183] In some embodiments, the IL-7 protein useful in the present disclosure comprises an IL-7 fusion protein. In certain embodiments, the IL-7 fusion protein comprises (i) an oligopeptide and (i) an IL-7 or variant thereof. In some embodiments, the oligopeptide is linked to the N-terminal region of the IL-7 or variant thereof.

[0184] In some embodiments, the oligopeptides disclosed herein consist of 1-10 amino acids. In certain embodiments, the oligopeptides consist of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or 10 amino acids. In some embodiments, one or more amino acids of the oligopeptide are selected from the group consisting of methionine, glycine, methionine-methionine, glycine-glycine, methionine-glycine, glycine-methionine, methionine-methionine-methionine, methionine-methionine-glycine, methionine-glycine-methionine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-methionine, methionine-glycine-glycine, glycine-methionine-glycine, glycine-methionine-glycine, glycine-glycine-methionine, and glycine-glycine-glycine. In some embodiments, the oligopeptide is methionine-glycine-methionine.

[0185] In some embodiments, the IL-7 fusion protein comprises (i) IL-7 or a variant thereof, and (ii) a half-life extending moiety. In some embodiments, the half-life extending moiety extends the half-life of IL-7 or a variant thereof. In some embodiments, the half-life extending moiety is linked to the C-terminal region of IL-7 or a variant thereof.

[0186] In some embodiments, the IL-7 fusion protein comprises (i) IL-7 (a first domain), (ii) a second domain comprising an amino acid sequence having 1-10 amino acid residues consisting of methionine, glycine, or a combination thereof, e.g., MGM, and (iii) a third domain comprising a half-life extending moiety. In some embodiments, the half-life extending moiety may be linked to the N-terminus or C-terminus of the first domain or the second domain. Additionally, the IL-7 comprising the first domain and the second domain may be linked to both termini of the third domain.

[0187] Non-limiting examples of half-life extending moieties include Fc, albumin, albumin binding polypeptide, Pro / Ala / Ser (PAS), C-terminal peptide of the beta subunit of human chorionic gonadotropin (CTP), polyethylene glycol (PEG), long unstructured hydrophilic amino acid sequences (XTEN), hydroxyethyl starch (HES), albumin binding small molecules, and combinations thereof.

[0188] In some embodiments, the half-life extending moiety is an Fc. In certain embodiments, the Fc is derived from a modified immunoglobulin in which antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) is attenuated by modifying the binding affinity with the Fc receptor and / or complement. In some embodiments, the modified immunoglobulin may be selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE, and combinations thereof. In some embodiments, the Fc is a hybrid Fc ("hFc" or "hyFc") comprising a hinge region, a CH2 domain, and a CH3 domain. In certain embodiments, the hinge region of the hybrid Fc disclosed herein comprises a human IgD hinge region. In certain embodiments, the CH2 domain of the hybrid Fc comprises a portion of a human IgD CH2 domain and a portion of a human IgG4 CH2 domain. In certain embodiments, the CH3 domain of the hybrid Fc comprises a portion of a human IgG4 CH3 domain. Thus, in some aspects, the hybrid Fc disclosed herein comprises a hinge region, a CH2 domain, and a CH3 domain, wherein the hinge region comprises a human IgD hinge region, the CH2 domain comprises a portion of a human IgD CH2 domain and a portion of a human IgG4 CH2 domain, and the CH3 domain comprises a portion of a human IgG4 CH3 domain.

[0189] In some embodiments, the Fc disclosed herein may be an Fc variant. As used herein, the term "Fc variant" refers to an Fc prepared by substituting a portion of amino acids in the Fc region or combining different types of Fc regions. The Fc region variant can be prevented from being cleaved at the hinge region. In particular, in some embodiments, the Fc variant comprises a modification of the 144th and / or 145th amino acids of SEQ ID NO:9. In certain embodiments, the 144th amino acid (K) and / or the 145th amino acid (K) are substituted with G or S.

[0190] In some embodiments, the Fc or Fc variant disclosed herein can be represented by the formula: N'-(Z1)pY-Z2-Z3-Z4-C, wherein: N' comprises the N-terminus, Z1 comprises an amino acid sequence having 5 to 9 consecutive amino acid residues from the amino acid residue at position 98 toward the N-terminus among the amino acid residues at positions 90 to 98 of SEQ ID NO: 7, Y comprises an amino acid sequence having 5 to 64 consecutive amino acid residues from the amino acid residue at position 162 to the N-terminus among the amino acid residues at positions 99 to 162 of SEQ ID NO: 7, Z2 comprises an amino acid sequence having 4 to 37 consecutive amino acid residues from the amino acid residue at position 163 toward the C-terminus among the amino acid residues at positions 163 to 199 of SEQ ID NO: 7; Z3 comprises an amino acid sequence having 71 to 106 consecutive amino acid residues from the amino acid residue at position 220 toward the N-terminus among the amino acid residues at positions 115 to 220 of SEQ ID NO:8, Z4 comprises an amino acid sequence having 80 to 107 consecutive amino acid residues from the amino acid residue at position 221 to the C-terminus among the amino acid residues at positions 221 to 327 of SEQ ID NO:8.

[0191] In some embodiments, the Fc region disclosed herein may comprise the amino acid sequence of SEQ ID NO:9 (hyFc), SEQ ID NO:10 (hyFcM1), SEQ ID NO:11 (hyFcM2), SEQ ID NO:12 (hyFcM3), or SEQ ID NO:13 (hyFcM4). In some embodiments, the Fc region may comprise the amino acid sequence of SEQ ID NO:14 (non-lytic mouse Fc).

[0192] Other non-limiting examples of Fc regions that can be used in the present disclosure are described in US Pat. No. 7,867,491, which is incorporated by reference in its entirety.

[0193] In some embodiments, the IL-7 fusion proteins disclosed herein comprise both an oligopeptide and a half-life extending moiety.

[0194] In some embodiments, the IL-7 protein may be fused to albumin, a variant, or a fragment thereof. An example of an IL-7-albumin fusion protein can be found in International Application Publication No. WO2011 / 124718A1. In some embodiments, the IL-7 protein is fused to pre-pro-B cell growth stimulatory factor (PPBSF), optionally by a flexible linker. See US2002 / 0058791A1. In other embodiments, the IL-7 protein useful in the present disclosure is an IL-7 conformer having a specific three-dimensional structure. See US2005 / 0249701A1. In some embodiments, the IL-7 protein may be fused to an Ig chain, where amino acid residues 70 and 91 of the IL-7 protein are glycosylated and amino acid residue 116 of the IL-7 protein is not glycosylated. See US7,323,549B2. In some embodiments, IL-7 proteins that do not contain potential T cell epitopes (and thus reduce anti-IL-7 T cell responses) may also be used in the present disclosure. See US2006 / 0141581A1. In other embodiments, IL-7 proteins with one or more amino acid residue mutations in the carboxy-terminal helix D region may be used in the present disclosure. IL-7 mutants may act as partial agonists of IL-7R despite having a low binding affinity to the receptor. See US2005 / 0054054A1. Any IL-7 proteins described in the above patents or publications are incorporated herein by reference in their entirety.

[0195] Further non-limiting examples of additional IL-7 proteins useful in the present disclosure include those described in US7708985, US8034327, US8153114, US7589179, US7323549, US7960514, US8338575, US7118754, US7488482, US7670607, US6730512, WO0017362, GB2434578A, WO2010 / 020766A2, WO91 / 01143, Beq et al. al., Blood, vol. 114(4), 816, 23 July 2009; Kang et al., J. Virol. Doi: 10.1128 / JVI.02768-15; Martin et al., Blood, vol. 121(22), 4484, May 30, 2013; McBride et al., Acta Oncologica, 34: 3, 447-451, July 8, 2009; and Xu et al., Cancer Science, 109: 279-288, 2018, which are incorporated by reference in their entireties.

[0196] The present disclosure relates to a method of treating a tumor (or cancer) in a subject in need thereof, comprising administering to the subject an effective amount of an interleukin-7 (IL-7) protein in combination with an effective amount of an immune checkpoint inhibitor. Non-limiting examples of immune checkpoint inhibitors that can be used in the methods of the invention include anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, and combinations thereof.

[0197] In some embodiments, the oligopeptide disclosed herein is directly linked to the N-terminal region of IL-7 or a variant thereof. In other embodiments, the oligopeptide is linked to the N-terminal region via a linker. In some embodiments, the half-life extending moiety disclosed herein is directly linked to the C-terminal region of IL-7 or a variant thereof. In certain embodiments, the half-life extending moiety is linked to the C-terminal region via a linker. In some embodiments, the linker is a peptide linker. In certain embodiments, the peptide linker comprises a peptide of 10-20 amino acid residues consisting of Gly and Ser residues. In some embodiments, the linker is an albumin linker. In some embodiments, the linker is a chemical bond. In certain embodiments, the chemical bond comprises a disulfide bond, a diamine bond, a sulfide-amine bond, a carboxy-amine bond, an ester bond, a covalent bond, or a combination thereof. When the linker is a peptide linker, in some embodiments, the bond can occur at any linking region. These can be bonded using crosslinkers known in the art. In some embodiments, examples of crosslinkers can include, but are not limited to, imidoesters including N-hydroxysuccinimide esters such as 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, and 4-azidosalicylic acid; disuccinimidyl esters such as 3,3'-dithiobis(succinimidyl propionate); and bifunctional maleimides such as bis-N-maleimide-1,8-octane.

[0198] In some embodiments, the IL-7 (or variant thereof) portion of an IL-7 fusion protein disclosed herein comprises an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NOs: 15-20. In certain embodiments, the IL-7 (or variant thereof) portion of an IL-7 fusion protein disclosed herein comprises the amino acid sequence set forth in SEQ ID NOs: 15-20.

[0199] In some embodiments, the IL-7 fusion protein comprises a first domain comprising a polypeptide having an activity of IL-7 or an activity similar thereto, a second domain comprising an amino acid sequence having 1 to 10 amino acid residues consisting of methionine, glycine, or a combination thereof, and a third domain which is a modified immunoglobulin Fc region attached to the C-terminus of the first domain.

[0200] In some embodiments, IL-7 fusion proteins that can be used in the methods of the invention comprise an amino acid sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 98%, or at least 99% identical to the amino acid sequences set forth in SEQ ID NOs: 21-25. In certain embodiments, IL-7 fusion proteins of the present disclosure comprise the amino acid sequences set forth in SEQ ID NOs: 21-25. In further embodiments, IL-7 fusion proteins disclosed herein comprise the amino acid sequences set forth in SEQ ID NOs: 26 and 27.

[0201] In some embodiments, the IL-7 protein useful in the present disclosure can increase the absolute lymphocyte count of a subject when administered to the subject. In certain embodiments, the subject suffers from a disease or disorder (e.g., cancer) described herein. In other embodiments, the subject is a healthy individual (e.g., does not suffer from a disease or disorder (e.g., cancer) described herein). In certain embodiments, the absolute lymphocyte count is increased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% or more compared to a reference (e.g., a corresponding level in a subject that did not receive the IL-7 protein).

[0202] In some embodiments, the IL-7 proteins disclosed herein enhance T cell proliferation (e.g., CD8 + T cells) that proliferate in response to IL-7 administration. In certain embodiments, the increase in T cell proliferation occurs in the periphery (e.g., other than within a tumor). In certain embodiments, T cell proliferation is increased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% or more compared to a reference (e.g., corresponding levels in a subject that did not receive IL-7 protein). In certain embodiments, T cells (e.g., CD8 + T cells) express one or more of the following markers: Eomesodermin (Eomes), Granzyme B, CXCR3, IFN-γ, or a combination thereof.

[0203] In some embodiments, the IL-7 proteins of the present disclosure are used to recruit effector T cells (e.g., cytotoxic CD8 + In certain embodiments, the recruitment of effector T cells to the tumor is increased by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% or more compared to a reference (e.g., a corresponding level in a subject that did not receive the IL-7 protein).

[0204] In some embodiments, the IL-7 proteins of the present disclosure may reduce the number and / or percentage of myeloid-derived suppressor cells (MDSCs) in a tumor of a subject. In certain embodiments, the number and / or percentage of MDSCs in a tumor is reduced by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% compared to a reference (e.g., a corresponding level in a subject that did not receive the IL-7 protein).

[0205] In some embodiments, the IL-7 protein that can be used in the present disclosure, when administered to a subject, inhibits CD8 in tumors. + The ratio of TILs to MDSCs can be increased. In certain embodiments, CD8 +The ratio of TILs to MDSCs is increased by at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 125%, at least about 150%, at least about 200%, at least about 250%, or at least about 300% after administration compared to a reference (e.g., a corresponding level in a subject that did not receive the IL-7 protein).

[0206] IIb. PD-1 antagonists In some embodiments, the disclosure provides a method of treating a tumor in a subject in need thereof comprising administering to the subject an effective amount of an IL-7 protein in combination with an effective amount of a PD-1 pathway antagonist ("PD-1 antagonist"). As used herein, the term "PD-1 antagonist" may be used synonymously with the term "PD-1 pathway inhibitor" and includes, but is not limited to, PD-1-binding agents, PD-L1-binding agents, and PD-L2-binding agents. PD-1-binding agents include antibodies that specifically bind to PD-1. PD-L1-binding agents and PD-L2-binding agents include antibodies that specifically bind to PD-L1 and / or PD-L2, as well as soluble PD-1 polypeptides that bind to PD-L1 and / or PD-L2.

[0207] Anti-PD-1 antibody In some embodiments, the PD-1 antagonist that can be used in the present disclosure is an anti-PD-1 antibody. Antibodies (e.g., human antibodies) that specifically bind to PD-1 with high affinity are disclosed in U.S. Patent Nos. 8,008,449 and 8,779,105, each of which is incorporated herein by reference. Other anti-PD-1 mAbs are described, for example, in U.S. Patent Nos. 6,808,710, 7,488,802, 8,168,757, and 8,354,509, and PCT Publication No. WO2012 / 145493, each of which is incorporated herein by reference. Each of the anti-PD-1 HuMAbs disclosed in U.S. Patent No. 8,008,449 has been shown to exhibit one or more of the following characteristics: (a) a PD-1 specific binding affinity of 1×10 6 as determined by surface plasmon resonance using a Biacore biosensor system; -7 K below M D (b) binds to human PD-1 in a mixed lymphocyte reaction (MLR) assay; (c) increases T cell proliferation in a mixed lymphocyte reaction (MLR) assay; (d) increases interferon-γ production in a MLR assay; (e) increases IL-2 secretion in a MLR assay; (f) binds to human PD-1 and cynomolgus PD-1; (g) inhibits binding of PD-L1 and / or PD-L2 to PD-1; (h) stimulates an antigen-specific memory response; (i) stimulates an Ab response; and (j) inhibits tumor cell growth in vivo. Anti-PD-1 antibodies useful in the present invention include mAbs that specifically bind human PD-1 and exhibit at least one, and preferably at least five, of the aforementioned characteristics.

[0208] In some embodiments, the anti-PD-1 antibody is nivolumab. Nivolumab (also known as "OPDIVO®"; 5C4, BMS-936558, MDX-1106, or ONO-4538) is a fully human IgG4 (S228P) PD-1 immune checkpoint inhibitor antibody that selectively prevents interaction with PD-1 ligands (PD-L1 and PD-L2), thereby preventing downregulation of anti-tumor T cell function (U.S. Patent No. 8,008,449; Wang et al., 2014 Cancer Immunol Res. 2(9):846-56, each of which is incorporated herein by reference). In some embodiments, the anti-PD-1 antibody or fragment thereof cross-competes with nivolumab. In other embodiments, the anti-PD-1 antibody or fragment thereof binds to the same epitope as nivolumab. In certain embodiments, the anti-PD-1 antibody has the same CDRs as nivolumab. In some embodiments, the anti-PD-1 antibody (e.g., nivolumab) is administered to the subject (e.g., in combination with an IL-7 protein disclosed herein) at a fixed dose of about 240 mg every two weeks or about 480 mg every four weeks. In certain embodiments, the anti-PD-1 antibody (e.g., nivolumab) is administered at a weight basis dose of about 3 mg / kg every two weeks.

[0209] Anti-PD-1 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the present invention can be generated using methods well known in the art. Alternatively, art-recognized anti-PD-1 antibodies may be used. For example, monoclonal antibodies 5C4 (referred to herein as nivolumab or BMS-936558), 17D8, 2D3, 4H1, 4A11, 7D3, and 5F4, described in WO2006 / 121168, the teachings of which are incorporated herein by reference, can be used. Other known PD-1 antibodies include lambrolizumab (MK-3475), described in WO2008 / 156712, and AMP-514, described in WO2012 / 145493, the teachings of which are incorporated herein by reference. Additional known anti-PD-1 antibodies and other PD-1 inhibitors include those described in WO2009 / 014708, WO03 / 099196, WO2009 / 114335, and WO2011 / 161699, the teachings of which are incorporated herein by reference. Another known anti-PD-1 antibody is pidilizumab (CT-011). Antibodies or antigen-binding fragments thereof that compete with any of these antibodies or inhibitors for binding to PD-1 can also be used.

[0210] In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof cross-competes with pembrolizumab. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof binds to the same epitope as pembrolizumab. In certain embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof has the same CDRs as pembrolizumab. In another embodiment, the anti-PD-1 antibody is pembrolizumab. Pembrolizumab (also known as "KEYTRUDA®", lambrolizumab, and MK-3475) is a humanized IgG4 monoclonal antibody against the human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1). Pembrolizumab is described, for example, in U.S. Patent Nos. 8,354,509 and 8,900,587. Also see worldwideweb.cancer.gov / drugdictionary?cdrid=695789 (last accessed May 25, 2017). Each of these is incorporated herein by reference. Pembrolizumab is FDA approved for the treatment of recurrent or refractory melanoma. In some embodiments, the anti-PD-1 antibody (e.g., pembrolizumab) is administered to the subject (e.g., in combination with an IL-7 protein disclosed herein) at a fixed dose of about 200 mg every three weeks. In certain embodiments, the anti-PD-1 antibody (e.g., pembrolizumab) is administered at a weight basis dose of about 2 mg / kg every three weeks.

[0211] In other embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof cross-competes with MEDI0608. In yet other embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof binds to the same epitope as MEDI0608. In certain embodiments, the anti-PD-1 antibody has the same CDRs as MEDI0608. In other embodiments, the anti-PD-1 antibody is the monoclonal antibody MEDI0608 (formerly AMP-514). MEDI0608 is described, for example, in U.S. Patent No. 8,609,089 or worldwideweb.cancer.gov / drugdictionary?cdrid=756047 (last accessed May 25, 2017), each of which is incorporated herein by reference.

[0212] In other embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof cross-competes with BGB-A317. In some embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof binds to the same epitope as BGB-A317. In certain embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof has the same CDRs as BGB-A317. In certain embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is the humanized monoclonal antibody BGB-A317. BGB-A317 is described in U.S. Publication No. 2015 / 0079109, which is incorporated herein by reference.

[0213] In some embodiments, the antibody or antigen-binding fragment thereof that cross-competes with nivolumab for binding to human PD-1 or binds to the same epitope region of human PD-1 as nivolumab is a mAb. For administration to human subjects, these cross-competing antibodies may be chimeric, humanized or human antibodies. Such chimeric, humanized or human mAbs can be prepared and isolated by methods well known in the art.

[0214] Anti-PD-1 antibodies or antigen-binding fragments thereof suitable for use in the present disclosure are those that bind to PD-1 with high specificity and affinity, block the binding of PD-L1 and / or PD-L2, and inhibit the immunosuppressive effects of the PD-1 signaling pathway. In certain embodiments, the anti-PD-1 antibody or antigen-binding portion thereof cross-competes with nivolumab for binding to human PD-1. In other embodiments, the anti-PD-1 antibody or antigen-binding portion thereof is a chimeric, humanized, or human monoclonal antibody, or a portion thereof. In certain embodiments, the antibody is a humanized antibody. In other embodiments, the antibody is a human antibody. Antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype can be used.

[0215] In certain embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain constant region that is of a human IgG1 or IgG4 isotype. In certain other embodiments, the sequence of the IgG4 heavy chain constant region of the anti-PD-1 antibody or antigen-binding fragment thereof comprises a S228P mutation, replacing a serine residue in the hinge region with a proline residue normally found at the corresponding position in IgG1 isotype antibodies. This mutation is present in nivolumab, which prevents Fab arm exchange with endogenous IgG4 antibodies while retaining the low affinity for activating Fc receptors associated with wild-type IgG4 antibodies (Wang et al., 2014). In still other embodiments, the antibody comprises a light chain constant region that is a human kappa or lambda constant region. In other embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof is a mAb or antigen-binding portion thereof. In certain embodiments of any of the therapeutic methods described herein that include administration of an anti-PD-1 antibody, the anti-PD-1 antibody is nivolumab. In other embodiments, the anti-PD-1 antibody is pembrolizumab. In other embodiments, the anti-PD-1 antibody is selected from human antibodies 17D8, 2D3, 4H1, 4A11, 7D3, and 5F4, which are described in U.S. Patent No. 8,008,449, incorporated herein by reference. In yet other embodiments, the anti-PD-1 antibody is MEDI0608 (formerly known as AMP-514), AMP-224, or pidilizumab (CT-011).

[0216] Anti-PD-L1 antibody In some embodiments, the PD-1 antagonist that can be used in the present disclosure is an anti-PD-L1 antibody. Anti-human PD-L1 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the present invention can be generated using methods well known in the art. Alternatively, art-recognized anti-PD-L1 antibodies can be used. For example, the human anti-PD-L1 antibodies disclosed in U.S. Patent No. 7,943,743, the contents of which are incorporated herein by reference, can be used. Such anti-PD-L1 antibodies include 3G10, 12A4 (also known as BMS-936559), 10A5, 5F8, 10H10, 1B12, 7H1, 11E6, 12B7, and 13G4. Other art-recognized anti-PD-L1 antibodies that can be used include, for example, those described in U.S. Patent Nos. 7,635,757 and 8,217,149, U.S. Publication No. 2009 / 0317368, and PCT Publication Nos. WO2011 / 066389 and WO2012 / 145493, the teachings of which are also incorporated herein by reference. Other examples of anti-PD-L1 antibodies include atezolizumab (TECENTRIQ®; RG7446), or durvalumab (IMFINZI®; MEDI4736). Antibodies or antigen-binding fragments thereof that compete for binding to PD-L1 with any of these art-recognized antibodies or inhibitors can also be used. In some embodiments, an anti-PD-L1 antibody (e.g., atezolizumab) is administered to a subject (e.g., in combination with an IL-7 protein disclosed herein) at a dose of about 1200 mg every three weeks. In some embodiments, an anti-PD-L1 antibody (e.g., durvalumab) is administered to a subject (e.g., in combination with an IL-7 protein disclosed herein) at a dose of about 10 mg / kg every two weeks.

[0217] In a particular embodiment, the anti-PD-L1 antibody is BMS-936559 (formerly known as 12A4 or MDX-1105) (see, e.g., U.S. Patent No. 7,943,743; WO2013 / 173223, both of which are incorporated by reference herein). In other embodiments, the anti-PD-L1 antibody is MPDL3280A (also known as RG7446 and atezolizumab) (see, e.g., Herbst et al. 2013 J Clin Oncol 31(suppl):3000; U.S. Patent No. 8,217,149, both of which are incorporated herein by reference), MEDI4736 (Khleif, 2013, In: Proceedings from the European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract 802, which is incorporated herein by reference), or MSB0010718C (also known as avelumab; see US2014 / 0341917, which is incorporated herein by reference). In certain embodiments, the antibody that cross-competes with the above-referenced PD-L1 antibodies for binding to human PD-L1 or binds to the same epitope region of human PD-L1 as the above-referenced PD-L1 antibodies is a mAb. For administration to a human subject, these cross-competing antibodies may be chimeric antibodies, or may be humanized or human antibodies. Such chimeric, humanized or human mAbs can be prepared and isolated by methods well known in the art. In some embodiments, the anti-PD-L1 antibody (e.g., avelumab) is administered to the subject (e.g., in combination with an IL-7 protein disclosed herein) at a dose of about 800 mg every two weeks.

[0218] IIc. CTLA-4 antagonists In some embodiments, the present disclosure also provides a method of treating a tumor in a subject in need thereof, comprising administering to the subject an effective amount of an IL-7 protein in combination with an effective amount of a CTLA-4 pathway antagonist ("CTLA-4 antagonist"). In some embodiments, the CTLA-4 antagonist is an anti-CTLA-4 antibody.

[0219] HuMAbs that specifically bind CTLA-4 with high affinity are disclosed in U.S. Patent Nos. 6,984,720 and 7,605,238, each of which is incorporated herein by reference. Other anti-CTLA-4 mAbs are described, for example, in U.S. Patent Nos. 5,977,318, 6,051,227, 6,682,736, and 7,034,121, each of which is incorporated herein by reference. The anti-CTLA-4 HuMAbs disclosed in U.S. Patent Nos. 6,984,720 and 7,605,238, both of which are incorporated herein by reference, have been shown to exhibit one or more of the following characteristics: (a) a CTLA-4 affinity of at least about 10 as determined by Biacore analysis; 7 M -1 , or about 10 9 M -1 , or about 10 10 M -1 ~10 11 M -1 The equilibrium association constant (K a (b) specifically binds to human CTLA-4 with a binding affinity reflected by at least about 10 3 , about 10 4 , or about 10 5 m -1 s -1 The kinetic association constant (k a );(c) at least about 10 3 , about 10 4 , or about 10 5 m -1 s -1 The kinetic dissociation constant (k dand (d) inhibit the binding of CTLA-4 to B7-1 (CD80) and B7-2 (CD86). Anti-CTLA-4 antibodies useful in the present invention include mAbs that specifically bind human CTLA-4 and exhibit at least one, at least two, or at least three of the aforementioned characteristics. An exemplary clinical anti-CTLA-4 antibody is human mAb 10D1 (now known as ipilimumab and commercially available as YERVOY®), disclosed in U.S. Pat. No. 6,984,720, which is incorporated herein by reference. Ipilimumab is an anti-CTLA-4 antibody used in the methods disclosed herein. Ipilimumab is a fully human IgG1 monoclonal antibody that blocks CTLA-4 from binding to its B7 ligand, thereby stimulating T cell activation and improving overall survival (OS) in patients with advanced melanoma. In some embodiments, an anti-CTLA-4 antibody (e.g., ipilimumab) is administered to a subject (e.g., in combination with an IL-7 protein disclosed herein) at a dose of about 3 mg / kg every three weeks (e.g., for treating unresectable or metastatic melanoma). In some embodiments, an anti-CTLA-4 antibody (e.g., ipilimumab) is administered to a subject (e.g., in combination with an IL-7 protein disclosed herein) at a dose of about 10 mg / kg every three weeks for four doses, followed by a dose of 10 mg / kg every 12 weeks for up to three years (e.g., for adjuvant treatment of melanoma).

[0220] Another anti-CTLA-4 antibody useful in the methods of the present invention is tremelimumab (also known as ticilimumab and CP-675,206). Tremelimumab is a human IgG2 monoclonal anti-CTLA-4 antibody. Tremelimumab is described in WO / 2012 / 122444, U.S. Publication No. 2012 / 263677, and WO Publication No. 2007 / 113648 A2, each of which is incorporated herein by reference. Other non-limiting examples of anti-CTLA-4 antibodies useful in the present disclosure include MK-1308 (Merck) and AGEN-1884 (Agenus Inc.; see WO2016 / 196237).

[0221] Anti-CTLA-4 antibodies useful in the present disclosure also include isolated antibodies that specifically bind to human CTLA-4 and cross-compete with ipilimumab, tremelimumab, MK-1308, or AGEN-1884 for binding to human CTLA-4, or bind to the same epitope region of human CTLA-4 as ipilimumab, tremelimumab, MK-1308, or AGEN-18844.In certain embodiments, the antibody that cross-competes with ipilimumab, tremelimumab, MK-1308, or AGEN-18844 for binding to human CTLA-4, or binds to the same epitope region of human CTLA-4 as ipilimumab, tremelimumab, MK-1308, or AGEN-18844 binds to is an antibody that comprises a heavy chain of human IgG1 isotype.When administered to human subjects, these cross-competing antibodies are chimeric antibodies, or humanized or human antibodies. Antigen-binding portions of the above antibodies, such as Fab, F(ab')2, Fd, or Fv fragments, may be used in the methods of the invention.

[0222] III. Nucleic Acids, Vectors, and Host Cells Further aspects described herein relate to one or more nucleic acid molecules encoding the therapeutic agents described herein (e.g., IL-7 proteins). The nucleic acid may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. A nucleic acid is "isolated" or "substantially pure" when it has been purified from other cellular components or other contaminants, such as other cellular nucleic acids (e.g., other chromosomal DNA, e.g., chromosomal DNA naturally linked to the isolated DNA) or proteins, by standard techniques including alkaline / SDS treatment, CsCl banding, column chromatography, restriction enzymes, agarose gel electrophoresis, and other techniques well known in the art. See F. Ausubel, et al., ed. (1987) Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York. The nucleic acids described herein may be, for example, DNA or RNA, and may or may not contain intron sequences. In certain embodiments, the nucleic acid is a cDNA molecule. The nucleic acids described herein can be obtained using standard molecular biology techniques known in the art.

[0223] Certain nucleic acid molecules disclosed herein are those that encode IL-7 proteins (e.g., those disclosed herein). Exemplary nucleic acid sequences encoding the IL-7 proteins disclosed herein are set forth in SEQ ID NOs: 29-39.

[0224] In some embodiments, the present disclosure provides a vector comprising an isolated nucleic acid molecule encoding a therapeutic agent (e.g., an IL-7 protein) disclosed herein. In some embodiments, the vector can be used in gene therapy.

[0225] When used as gene therapy (e.g., in humans), nucleic acids encoding a therapeutic agent disclosed herein (e.g., an IL-7 protein) may be administered at a dosage in the range of 0.1 mg to 200 mg. In certain embodiments, the dosage is in the range of 0.6 mg to 100 mg. In further embodiments, the dosage is in the range of 1.2 mg to 50 mg.

[0226] Suitable vectors for this disclosure include expression vectors, viral vectors, and plasmid vectors. In some embodiments, the vector is a viral vector.

[0227] As used herein, an expression vector refers to any nucleic acid construct that, upon introduction into an appropriate host cell, contains the necessary elements for the transcription and translation of an inserted coding sequence, or, in the case of RNA viral vectors, the elements necessary for replication and translation. Expression vectors can include plasmids, phagemids, viruses, and their derivatives.

[0228] As used herein, viral vectors include, but are not limited to, the following viruses: retroviruses, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, mouse mammary tumor virus, and Rous sarcoma virus; lentivirus; adenovirus; adeno-associated virus; SV40-type virus; polyoma virus; Epstein-Barr virus; papilloma virus; herpes virus; vaccinia virus; polio virus; and nucleic acid sequences derived from RNA viruses, such as retroviruses. Other vectors well known in the art can also be readily used. Certain viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with a gene of interest. Non-cytopathic viruses include retroviruses, whose life cycle involves reverse transcription of genomic viral RNA into DNA, followed by proviral integration into host cell DNA.

[0229] In some embodiments, the vector is derived from an adeno-associated virus. In other embodiments, the vector is derived from a lentivirus. Examples of lentivirus vectors are disclosed in WO9931251, WO9712622, WO9817815, WO9817816, and WO9818934, each of which is incorporated herein by reference in its entirety.

[0230] Other vectors include plasmid vectors. Plasmid vectors have been widely reported in the art and are well known to those skilled in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the past few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells in vivo because they do not replicate and integrate into the host genome. However, these plasmids with promoters compatible with the host cell can express peptides from genes operably encoded within the plasmid. Some commonly used plasmids available from commercial suppliers include pBR322, pUC18, pUC19, various pcDNA plasmids, pRC / CMV, various pCMV plasmids, pSV40, and pBlueScript. Further examples of specific plasmids include pcDNA3.1, catalog number V79020; pcDNA3.1 / hygro, catalog number V87020; pcDNA4 / myc-His, catalog number V86320; and pBudCE4.1, catalog number V53220, all from Invitrogen (Carlsbad, Calif.). Other plasmids will be known to those of skill in the art. Additionally, plasmids can be custom designed using standard molecular biology techniques to remove and / or add specific DNA fragments.

[0231] The present disclosure also encompasses methods of making the therapeutic agents (e.g., IL-7 proteins) disclosed herein. In some embodiments, such methods may include expressing the therapeutic agent (e.g., IL-7 proteins) in cells that contain a nucleic acid molecule encoding the therapeutic agent, e.g., SEQ ID NOs: 29-39. Further details regarding methods of making the IL-7 proteins disclosed herein are provided, for example, in WO2016 / 200219, which is incorporated herein by reference in its entirety. Host cells comprising these nucleotide sequences are encompassed herein. Non-limiting examples of host cells that can be used include immortal hybridoma cells, NS / 0 myeloma cells, 293 cells, Chinese hamster ovary (CHO) cells, HeLa cells, human amniotic fluid-derived cells (CapT cells), COS cells, or combinations thereof.

[0232] IV. Pharmaceutical Compositions Further provided herein are compositions comprising one or more therapeutic agents (e.g., an IL-7 protein and / or an immune checkpoint inhibitor) at a desired purity and with a physiologically acceptable carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). In some embodiments, the compositions disclosed herein comprise an IL-7 protein or an immune checkpoint inhibitor. As disclosed herein, such compositions may be used in combination (e.g., a first composition comprising an IL-7 protein and a second composition comprising an immune checkpoint inhibitor). In other embodiments, the compositions disclosed herein may comprise both an IL-7 protein and an immune checkpoint inhibitor.

[0233] Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include buffers such as phosphate, citric acid, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol alcohol, butyl alcohol, or benzyl alcohol; alkyl parabens such as methyl paraben or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; These include proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, such as glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants, such as TWEEN®, PLURONICS®, or polyethylene glycol (PEG).

[0234] In some embodiments, the compositions disclosed herein (e.g., those comprising an IL-7 protein or an immune checkpoint inhibitor) comprise one or more additional components selected from a bulking agent, a stabilizer, a surfactant, a buffer, or a combination thereof.

[0235] Buffers useful in the present disclosure may be weak acids or weak bases used to maintain the acidity (pH) of a solution near a selected value after the addition of another acid or base. A suitable buffer can maximize the stability of a pharmaceutical composition by maintaining pH control of the composition. A suitable buffer can also ensure physiological compatibility or optimize solubility. Rheology, viscosity, and other properties may also depend on the pH of the composition. Common buffers include, but are not limited to, Tris buffer, Tris-Cl buffer, histidine buffer, TAE buffer, HEPES buffer, TBE buffer, sodium phosphate buffer, MES buffer, ammonium sulfate buffer, potassium phosphate buffer, potassium thiocyanate buffer, succinate buffer, tartaric acid buffer, DIPSO buffer, HEPPSO buffer, POPSO buffer, PIPES buffer, PBS buffer, MOPS buffer, acetate buffer, phosphate buffer, cacodylate buffer, glycine buffer, sulfate, phosphate buffer ... The buffer may be selected from the group consisting of acid buffer, imidazole buffer, guanidine hydrochloride buffer, phosphate-citrate buffer, borate buffer, malonate buffer, 3-picoline buffer, 2-picoline buffer, 4-picoline buffer, 3,5-lutidine buffer, 3,4-lutidine buffer, 2,4-lutidine buffer, Aces, diethyl malonate buffer, N-methylimidazole buffer, 1,2-dimethylimidazole buffer, TAPS buffer, Bis-Tris buffer, L-arginine buffer, lactate buffer, glycolic acid buffer, or combinations thereof.

[0236] In some embodiments, the compositions disclosed herein further comprise a bulking agent.Bulking agents may be added to pharmaceutical products to add volume and mass to the product, facilitating its accurate measurement and handling.The bulking agents that can be used in the present disclosure include, but are not limited to, sodium chloride (NaCl), mannitol, glycine, alanine, or combinations thereof.

[0237] In some embodiments, the compositions disclosed herein may include a stabilizer. Non-limiting examples of stabilizers that can be used in the present disclosure include sucrose, trehalose, raffinose, arginine, or combinations thereof.

[0238] In some embodiments, the composition disclosed herein comprises surfactant.In certain embodiments, surfactant can be selected from alkyl ethoxylate, nonylphenol ethoxylate, amine ethoxylate, polyethylene oxide, polypropylene oxide, fatty alcohol such as cetyl alcohol or oleyl alcohol, cocamide MEA, cocamide DEA, polysorbate, dodecyl dimethylamine oxide, or combinations thereof.In some embodiments, surfactant is polysorbate 20 or polysorbate 80.

[0239] In some embodiments, a composition comprising an IL-7 protein can be formulated using the same formulation as the immune checkpoint inhibitor disclosed herein (e.g., used in combination with the IL-7 protein), hi other embodiments, the IL-7 protein and the immune checkpoint inhibitor are formulated using different formulations.

[0240] In some embodiments, the IL-7 protein disclosed herein is formulated in a composition comprising (a) a basal buffer, (b) a sugar, and (c) a surfactant. In certain embodiments, the basal buffer comprises histidine-acetate or sodium citrate. In some embodiments, the basal buffer is at a concentration of about 10 to about 50 nM. In some embodiments, the sugar comprises sucrose, trehalose, dextrose, or a combination thereof. In some embodiments, the sugar is present at a concentration of about 2.5 to about 5.0 w / v%. In further aspects, the surfactant is selected from polysorbates, polyoxyethylene alkyl ethers, polyoxyethylene stearates, alkyl sulfates, polyvinylpyridones, poloxamers, or combinations thereof. In some embodiments, the surfactant is at a concentration of about 0.05% to about 6.0 w / v%.

[0241] In some embodiments, the composition in which IL-7 is formulated further comprises an amino acid. In certain embodiments, the amino acid is selected from arginine, glutamic acid, glycine, histidine, or a combination thereof. In certain embodiments, the composition further comprises a sugar alcohol. Non-limiting examples of sugar alcohols include sorbitol, xylitol, maltitol, mannitol, or a combination thereof.

[0242] In some embodiments, the IL-7 protein disclosed herein is formulated in a composition comprising (a) sodium citrate (e.g., about 20 mM), (b) sucrose (e.g., about 5%), (c) sorbitol (e.g., about 1.5%), and (d) Tween 80 (e.g., about 0.05%).

[0243] In some embodiments, the IL-7 proteins of the present disclosure are formulated as described in WO2017 / 078385A1, which is incorporated herein in its entirety.

[0244] In some embodiments, a composition that can be used with an IL-7 protein disclosed herein comprises (i) nivolumab (OPDIVO®) (e.g., about 10 mg), (ii) mannitol (e.g., about 30 mg), (iii) pentetic acid (e.g., about 0.008 mg), (iv) polysorbate 80 (e.g., about 0.2 mg), (v) sodium chloride (e.g., about 2.92 mg), and (vi) anhydrous sodium citrate (e.g., about 5.88 mg). In certain embodiments, the composition may further comprise hydrochloric acid and / or sodium hydroxide to adjust the pH of the composition to about 6.

[0245] In some embodiments, a composition that can be used with the IL-7 proteins disclosed herein comprises (i) pembrolizumab (KEYTRUDA®) (e.g., about 25 mg), (ii) L-histidine (e.g., about 1.55 mg), (iii) polysorbate 80 (e.g., about 0.2 mg), and (iv) sucrose (e.g., about 70 mg). In certain embodiments, the composition may further comprise hydrochloric acid and / or sodium hydroxide to adjust the pH to about 5.5.

[0246] In some embodiments, a composition that can be used with an IL-7 protein disclosed herein comprises (i) atezolizumab (TECENTRIQ®) (e.g., about 60 mg), (ii) glacial acetic acid (e.g., about 16.5 mg), (iii) L-histidine (e.g., about 62 mg), (iv) sucrose (e.g., about 821.6 mg), and (v) polysorbate 20 (e.g., about 8 mg). In certain embodiments, the composition comprises hydrochloric acid and / or sodium hydroxide to adjust the pH to about 5.8.

[0247] In some embodiments, a composition that can be used with the IL-7 proteins disclosed herein includes (i) durvalumab (IMFINZI®) (e.g., about 50 mg), (ii) L-histidine (e.g., about 2 mg), (iii) L-histidine hydrochloride monohydrate (e.g., about 2.7 mg), (iv) α,α-trehalose dihydrate (e.g., about 104 mg), and (v) polysorbate 80 (e.g., about 0.2 mg).

[0248] In some embodiments, a composition that can be used with the IL-7 proteins disclosed herein includes (i) ipilimumab (YERVOY®) (e.g., about 5 mg), (ii) diethylenetriaminepentaacetic acid (DTPA) (e.g., about 0.04 mg), (iii) mannitol (e.g., about 10 mg), (iv) polysorbate 80 (vegetable derived) (e.g., about 0.1 mg), (v) sodium chloride (e.g., about 5.85 mg), and (vi) Tris hydrochloride (e.g., about 3.15 mg).

[0249] In some embodiments, a composition that can be used with the IL-7 proteins disclosed herein includes (i) avelumab (BAVENCIO®) (e.g., about 20 mg), (ii) D-mannitol (e.g., about 51 mg), (iii) glacial acetic acid (e.g., about 0.6 mg), (iv) polysorbate 20 (e.g., about 0.5 mg), and (v) sodium hydroxide (e.g., about 0.3 mg).

[0250] The pharmaceutical composition may be formulated for any route of administration to a subject. Specific examples of routes of administration include intramuscular, subcutaneous, ophthalmic, intravenous, intraperitoneal, intradermal, intraorbital, intracerebral, intracranial, intraspinal, intraventricular, intrathecal, intracisternal, intracapsular, or intratumoral. Parenteral administration, characterized by injection, either subcutaneous, intramuscular, or intravenous, is also contemplated herein. Injectables may be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Injectables, solutions, and emulsions also include one or more excipients. Suitable excipients are, for example, water, saline, dextrose, glycerol, or ethanol. In addition, if desired, the pharmaceutical composition to be administered may contain minor amounts of nontoxic auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as, for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and cyclodextrins.

[0251] Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents, and other pharma- ceutically acceptable substances. Examples of aqueous vehicles include sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose, and lactated Ringer's injection. Non-aqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, and peanut oil. Antimicrobial agents may be added in bacteriostatic or fungistatic concentrations to parenteral preparations packaged in multi-dose containers, including phenol or cresol, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride, and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Emulsifying agents include polysorbate 80 (TWEEN® 80). Sequestering or chelating agents of metal ions include EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol, and propylene glycol for water-miscible vehicles, and sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment.

[0252] Preparations for parenteral administration include sterile solutions ready for injection, sterile dry soluble products that are combined with a solvent immediately prior to use, such as lyophilized powders, subcutaneous tablets, sterile suspensions ready for injection, sterile dry insoluble products that are combined with a vehicle immediately prior to use, and sterile emulsions. The solutions may be either aqueous or non-aqueous.

[0253] If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), as well as solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol, and mixtures thereof.

[0254] Topical mixtures containing the antibody are prepared as described for local and systemic administration. The resulting mixture may be a solution, suspension, emulsion, etc., and may be formulated as a cream, gel, ointment, emulsion, solution, elixir, lotion, suspension, tincture, paste, foam, aerosol, irrigate, spray, suppository, bandage, skin patch, or any other formulation suitable for topical administration.

[0255] The antibodies or antigen-binding portions thereof described herein may be formulated as aerosols for local application, such as by inhalation (see, e.g., U.S. Pat. Nos. 4,044,126, 4,414,209, and 4,364,923, which describe aerosols for the delivery of steroids useful in the treatment of inflammatory diseases, particularly asthma). These formulations for administration to the respiratory tract may be in the form of an aerosol or solution for a nebulizer, or as a fine powder for insufflation, either alone or in combination with an inert carrier such as lactose. In such cases, the particles of the formulation have diameters of less than 50 microns in one embodiment, and less than 10 microns in one embodiment.

[0256] The therapeutic agents disclosed herein (e.g., IL-7 proteins) can be formulated for local or topical application, such as topical application to the skin and mucous membranes, e.g., the eye, in the form of gels, creams, and lotions, and for application to the eye, and for intracisternal or intraspinal application. Local administration is contemplated in transdermal delivery, as well as administration to the eye or mucous membranes, or in inhalation therapy. Nasal solutions of antibodies can also be administered alone or in combination with other pharma- ceutically acceptable excipients.

[0257] Transdermal patches, including iontophoretic and electrophoretic devices, are well known to those of skill in the art and can be used to administer antibodies. For example, such patches are disclosed in U.S. Patent Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010715, 5,985,317, 5,983,134, 5,948,433, and 5,860,957, each of which is incorporated herein by reference in its entirety.

[0258] In certain embodiments, the pharmaceutical composition comprising the therapeutic agent described herein (e.g., IL-7 protein or immune checkpoint inhibitor) is a lyophilized powder that can be reconstituted for administration as a solution, emulsion, and other mixture. It may also be reconstituted and formulated as a solid or gel. The lyophilized powder is prepared by dissolving the antibody or antigen-binding portion thereof described herein, or a pharma- ceutically acceptable derivative thereof, in a suitable solvent. In some embodiments, the lyophilized powder is sterile. The solvent may contain excipients or other pharmacological components of the powder that improve stability, or a reconstituted solution prepared from the powder. Excipients that can be used include, but are not limited to, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose, or other suitable agents. The solvent may also contain a buffer, such as citric acid, sodium phosphate, or potassium phosphate, or other such buffers known to those of skill in the art, in one embodiment at about neutral pH. The solution is then sterile filtered under standard conditions known to those of skill in the art, followed by lyophilization to provide the desired formulation. In some embodiments, the resulting solution can be apportioned into vials for lyophilization. Each vial can contain a single dose or multiple doses of the compound. The lyophilized powder can be stored under appropriate conditions, such as at about 4° C. to room temperature.

[0259] This lyophilized powder is reconstituted with water for injection to provide a formulation for use in parenteral administration. For reconstitution, the lyophilized powder is added to sterile water or other suitable carrier. The exact amount depends on the compound selected. Such amounts may be determined empirically.

[0260] The compositions provided herein may be formulated to target specific tissues, receptors, or other areas of the body of the subject to be treated. Many such targeting methods are well known to those skilled in the art. All such targeting methods are contemplated herein for use in the compositions of the present invention. Non-limiting examples of targeting methods are described, for example, in U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,071,570 ... See Nos. 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542, and 5,709,874.

[0261] Compositions to be used for in vivo administration can be sterile, readily accomplished, for example, by filtration through sterile filtration membranes.

[0262] The following examples are illustrative only and should not be construed as limiting the scope of the disclosure in any way, since numerous variations and equivalents will become apparent to those of skill in the art upon reading this disclosure. EXAMPLES

[0263] Example 1 Effect of combined treatment with IL-7 protein and PD-1 pathway inhibitor on tumor volume To evaluate the effect of the combination of IL-7 protein and PD-1 pathway inhibitors on tumor volume, a colon adenocarcinoma animal model was used. Briefly, MC-38 colon adenocarcinoma tumor cells (1 × 10 5, subcutaneously) into each C57BL / 6 mouse. Four days after tumor inoculation, the animals were subcutaneously administered IL-7 protein (1.25 mpk or 25 μg / mouse) or IL-7 formulation buffer. See FIG. 1A. The animals were then intraperitoneally administered anti-PD-1 antibody (5 mpk or 100 μg / mouse) or isotype control antibody on days 12, 15, and 18 after tumor inoculation. Tumor volumes were measured on days 8, 11, 13, 15, 18, and 20 after tumor inoculation. FIG. 1A is a graphical representation of the dosing schedule, and Table 1 (below) presents each treatment group. [Table 1]

[0264] Figures 1B and 1C provide the results of two different studies. As shown, animals treated with the combination therapy (IL-7 protein plus anti-PD-1 antibody) had significantly reduced tumor volume compared to control animals (i.e., those given only the IL-7 formulation buffer), as well as animals treated with either IL-7 protein or anti-PD-1 antibody alone.

[0265] Example 2 Effect of combined treatment with IL-7 protein and PD-1 pathway inhibitor on tumor-infiltrating lymphocytes To further evaluate the antitumor effect of the combination of IL-7 protein and PD-1 pathway inhibitors, MC-38 colon adenocarcinoma tumor cells (1 × 10 5 , subcutaneously) were also implanted into C57BL / 6 mice. Four days after tumor inoculation, animals were treated with a single dose of IL-7 protein (1.25 mpk or 25 μg / mouse, subcutaneously) or IL-7 formulation buffer. See FIG. 2A. Then, on days 9 and 12 after tumor inoculation, animals were treated with anti-PD-1 antibody (5 mpk or 100 μg / mouse, intraperitoneally) or isotype control antibody. Animals were sacrificed on day 14 after tumor inoculation, and tumor-infiltrating lymphocytes from each animal were analyzed by flow cytometry.

[0266] As shown in Figure 2B, animals treated with either anti-PD-1 antibody or IL-7 protein alone showed significantly reduced CD45 expression in the tumors of the animals. + Approximately 5-7% of cells are CD4 + This percentage was similar to that observed in control animals. However, in animals treated with the combination therapy (IL-7 protein + anti-PD-1 antibody), the tumor CD4 + A significant increase in the number of TILs was observed (CD45 + Approximately 10-12% of cells. As shown in Figure 2C, CD8 + For TILs, treatment with IL-7 protein alone moderately reduced CD8 T cells compared with both control and anti-PD-1 antibody-only treated animals. + When animals were treated with both IL-7 protein and anti-PD-1 antibody, CD45 + CD8 in cells + A further increase in TIL numbers was also observed.

[0267] Taken together, both the above results in Examples 1 and 2 indicate that a treatment regimen combining IL-7 protein and a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) can effectively treat cancer.

[0268] Example 3 Effect of triple combination of cyclophosphamide (CPA), IL-7 protein, and PD-1 pathway inhibitor on tumor volume and survival Next, the antitumor effects of combined treatment with IL-7 protein and PD-1 pathway inhibitors and chemotherapeutic agents (e.g., CPA) were evaluated in a colon adenocarcinoma animal model. Briefly, MC-38 colon adenocarcinoma tumor cells (1 × 10 5, subcutaneously) into C57BL / 6 mice. Then, 10 days after tumor inoculation, animals were intraperitoneally administered a single dose of CPA (100mpk or 2mg / mouse) or PBS. Two days after CPA administration, animals were subcutaneously administered IL-7 protein (10mpk or 200μg / mouse) or IL-7 formulation buffer. Starting from day 6 after CPA administration, animals were intraperitoneally administered anti-PD-1 antibody (5mpk or 100μg / mouse), anti-PD-L1-antibody (5mpk or 100μg / mouse), or isotype control antibody every 3 days for a total of 5 times (i.e., on days 6, 9, 12, 15, and 18 after CPA induction). See Figure 3A. Tumor volumes were measured on days 0, 1, 4, 6, 8, 11, 13, 15, 18, and 20 after CPA induction.

[0269] As shown in Figure 3B, animals treated with CPA and IL-7 protein ("3") had a significant reduction in tumor volume compared to animals treated with PBS ("1") or CPA alone ("2"). When either anti-PD1 antibody or anti-PD-L1 antibody was added to CPA and IL-7 protein, animals ("4" and "5", respectively) had further reductions in tumor volume. As shown in Figure 3C, increased reduction in tumor volume correlated with increased survival.

[0270] The above results indicate that combination therapy of IL-7 protein and PD-1 pathway inhibitors can be effectively used in combination with other anti-cancer drugs such as cyclophosphamide.

[0271] Example 4 Effect of combined treatment with IL-7 protein and PD-1 pathway inhibitor on tumor volume in thymectomy-induced lymphopenia As mentioned above, many anticancer drugs (...

Claims

[Claim 1] The invention described in this specification.

Citation Information

Patent Citations

  • Modified Interleukin-7 Protein and Its Use

    JP2018518955A